Novel substituted fluorinated n-propyl-pyrrolidine and n-propyl-azetidine compounds, methods for their preparation and therapeutic use thereof

By developing fluorinated N-propylpyrrolidine and N-propyl-azacyclobutane derivatives, the problem of resistance to ERα-positive breast cancer in existing endocrine therapies has been solved, achieving effective ERα degradation and therapeutic effects.

CN119013254APending Publication Date: 2024-11-22SANOFI SA(FR)
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202380033885.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-15
Filing Date
2023-04-14
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing endocrine therapies are effective for about one-third of ERα-positive breast cancer patients, but resistance often develops over time. There is a need to develop selective estrogen receptor degraders (SERDs) with good degradation efficacy to overcome resistance.

Method used

A series of novel fluorinated N-propylpyrrolidine and N-propyl-azacyclobutane derivatives were developed, which can effectively shut down ERα signaling by selectively antagonizing and degrading estrogen receptor α (ERα).

Benefits of technology

These compounds exhibit good ERα degradation capabilities, enabling them to overcome endocrine therapy resistance and providing new treatment options for ERα-positive breast cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119013254A_ABST
    Figure CN119013254A_ABST
Patent Text Reader

Abstract

Disclosed herein are compounds of Formula (I) or pharmaceutically acceptable salts thereof: wherein R1 and R2 independently represent a hydrogen atom or a deuterium atom; r3 represents a hydrogen atom, a-COOH group or a-OH group; r3'and R3 ''independently represent a hydrogen atom, a methyl group, a methoxyl group, a chlorine atom, a fluorine atom, or a cyano group; r4 represents a hydrogen atom or a fluorine atom; r5 and R5'independently represent a hydrogen atom or a fluorine atom; r6 represents a phenyl group, a fused phenyl group, a bicyclic group comprising 5 to 12 carbon atoms, a heteroaryl group comprising 2 to 9 carbon atoms and comprising from 1 to 3 heteroatoms, a cycloalkyl group comprising 3 to 7 carbon atoms, a (C3-C6) cycloalkyl (C1-C3) alkyl group, a 4 to 7 membered heterocycloalkyl group, a (C1-C6) alkyl group, or a phenyl (C1-C2) alkyl group; x represents-CH2-,-O-, or-S-; y represents-CH2-,-O-, or-NH-; r7 independently represents a (C1-C3) alkyl group such as a methyl group, a halogen atom such as a fluorine atom, a cyano group, or a (C1-C3) fluoroalkyl group such as a trifluoromethyl group; r8 represents a hydrogen atom, or a (C1-C3) alkyl group or cyclopropyl group; n is 0, 1 or 2; m is 0 or 1; and p is 0 or 1. Further disclosed are processes for preparing the same, pharmaceutical compositions comprising the same and the compounds of formula (I) for use as inhibitors and degrading agents of estrogen receptors, in particular in the treatment of ovulation dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hyperplasia or inflammation. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Disclosed herein are novel substituted fluorinated N-propyl-pyrrolidine and N-propyl-azetidine derivatives, methods for their preparation, and their therapeutic uses, particularly as anticancer agents via selective antagonism and degradation of estrogen receptors.

[0002] Estrogen receptor (ER) belongs to the steroid / nuclear receptor superfamily that participates in regulating differentiation in eukaryotic gene expression, cell proliferation and target tissues. ER is in two forms: estrogen receptor α (ERα) and estrogen receptor β (ERβ) encoded by ESR1 and ESR2 genes, respectively. ERα and ERβ are ligand-activated transcription factors, which are activated by the hormone estrogen (the most potent estrogen produced in vivo is 17β-estradiol). In the absence of hormones, ER is mainly located in the cytosol of cells. When the hormone estrogen binds to ER, ER migrates from the cytosol of cells to the nucleus, forms a dimer, and then binds to a specific genomic sequence called an estrogen response element (ERE). DNA / ER complexes interact with co-regulators to regulate the transcription of target genes.

[0003] ERα is mainly expressed in reproductive tissues such as uterus, ovary, breast, bone and white adipose tissue. Abnormal ERα signaling leads to the development of a variety of diseases such as cancer, metabolic and cardiovascular diseases, neurodegenerative diseases, inflammatory diseases and osteoporosis.

[0004] ERα is expressed in no more than 10% of normal breast epithelium, but is expressed in approximately 50%-80% of breast tumors. Such breast tumors with high levels of ERα are classified as ERα-positive breast tumors. The etiological role of estrogen in breast cancer is established, and regulation of ERα signaling remains an important approach to breast cancer treatment for most ERα-positive breast tumors. Currently, there are several strategies for inhibiting the estrogen axis in breast cancer, including: 1-Blocking estrogen synthesis through aromatase inhibitors for the treatment of early and late ERα-positive breast cancer patients; 2-Antagonizing estrogen ligand binding to ERα through tamoxifen for the treatment of ERα-positive breast cancer patients in both premenopausal and postmenopausal situations; 3-Antagonizing and downregulating ERα levels through Fulvestrant for the treatment of breast cancer in patients who have progressed despite endocrine therapy such as tamoxifen or aromatase inhibitors.

[0005] Although these endocrine therapies have greatly contributed to the reduction of breast cancer development, about more than one-third of ERα-positive patients show resistance to such existing therapies from the beginning or develop resistance over time. Several mechanisms have been described to explain resistance to such hormone therapies. For example, the hypersensitivity of ERα to low estrogen levels in the treatment with aromatase inhibitors, the switching of tamoxifen effects from antagonists to agonist effects or multiple growth factor receptor signaling pathways in tamoxifen treatment. ERα acquired mutations that occur after hormone therapy is initiated can also play a role in treatment failure and cancer progression. Certain mutations in ERα, particularly those identified in the ligand binding domain (LBD), lead to the ability to bind to DNA in the absence of a ligand and confer hormone independence in cells with such mutant receptors.

[0006] Most of the identified mechanisms of resistance to endocrine therapy rely on ERα-dependent activity. One of the new strategies to combat this resistance is to shut down ERα signaling by removing ERα from tumor cells using selective estrogen receptor degraders (SERDs). Clinical and preclinical data suggest that a number of resistance pathways can be circumvented by using SERDs.

[0007] There remains a need to provide SERDs with good degradation efficacy.

[0008] The documents WO 2017 / 140669, WO 2018 / 091153 and Youssef El-Ahmad et al.'s article (J. Med. Chem. [Journal of Medicinal Chemistry], 2020, 63, 512-528) disclose some substituted 6,7-dihydro-5H-benzo[7]annulene compounds and substituted N-(3-fluoropropyl)-pyrrolidine derivatives that can be used as SERDs. Such compounds have an O-pyrrolidine side chain in the para position and are (S) stereoisomers. However, James S. Scott et al.'s article (J. Med. Chem. [Journal of Medicinal Chemistry], 2023, 66, 2918-2945), which relates to SERD compounds having a tricyclic skeleton and a side chain containing a basic amine, shows that the change of the side chain from the para position to the meta position has an effect on the biological properties of the compound.

[0009] The inventors have now discovered novel compounds capable of selectively antagonizing and degrading estrogen receptors (SERD compounds) for use in cancer treatment.

[0010] Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts thereof:

[0011]

[0012] in:

[0013] - R1 and R2 independently represent a hydrogen atom or a deuterium atom;

[0014] -R3 represents a hydrogen atom, a -COOH group or a -OH group;

[0015] - R3′ and R3″ independently represent a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom, or a cyano group;

[0016] -R4 represents a hydrogen atom or a fluorine atom;

[0017] - R5 and R5' independently represent a hydrogen atom or a fluorine atom;

[0018] -R6 represents a group selected from the following:

[0019] ■ phenyl, which is optionally substituted by 1 to 3 substituents independently selected from the group consisting of a halogen atom; a (C1-C6)alkyl group optionally substituted by a cyano group or an -OH group; a (C1-C6)fluoroalkyl group; a (C3-C6)cycloalkyl group; a (C1-C6)alkoxy group; a (C1-C6)fluoroalkoxy group; a cyano group; a trifluoromethylsulfonyl group; a (C1-C4)alkylthio group; a (C1-C4)fluoroalkylthio group; a (C1-C4)alkylsulfonyl group; and an -OH group;

[0020] ■ a fused phenyl group selected from a phenyl group fused to a (C3-C6)cycloalkyl group, the (C3-C6)cycloalkyl ring of which optionally contains unsaturation, and wherein the fused phenyl group is optionally substituted with 1 to 3 substituents independently selected from a (C1-C3)alkyl group, a hydroxyl group, a halogen atom, a (C1-C6)fluoroalkyl group and a (C1-C3)alkoxy group;

[0021] a bicyclic group containing 5 to 12 carbon atoms, optionally containing 1 to 2 degrees of unsaturation; optionally substituted by 1 to 4 substituents independently selected from the group consisting of fluorine atoms, -OH groups, (C1-C3)alkyl groups, (C1-C3)fluoroalkyl groups, (C1-C3)alkoxy groups, (C1-C3)fluoroalkoxy groups and oxo groups;

[0022] a heteroaryl group containing 2 to 9 carbon atoms and containing from 1 to 3 heteroatoms independently selected from oxygen, nitrogen and sulfur and at least 5 atoms including carbon atoms and heteroatoms, such as a pyridyl group, a pyridone group or a pyrrolyl group, the heteroaryl group being optionally substituted by 1 to 3 substituents independently selected from a halogen atom, a (C1-C6)alkyl group, a (C1-C6)fluoroalkyl group, a (C1-C6)alkoxy group, a (C1-C6)fluoroalkoxy group, a cyano group, a carbamoyl group and a -OH group;

[0023] ■ a cycloalkyl group containing 3 to 7 carbon atoms, which is saturated or partially saturated and optionally substituted with 1 to 4 substituents independently selected from:

[0024] o fluorine atom, -OH group, (C1-C3) alkyl group, (C1-C3) fluoroalkyl group, (C1-C3) alkoxy group, (C1-C3) fluoroalkoxy group, oxo group,

[0025] o (C3-C6) cycloalkyl and phenyl, wherein the (C3-C6) cycloalkyl or phenyl is optionally substituted with one or two halogen atoms or (C1-C3) alkyl;

[0026] ■ (C3-C6)cycloalkyl (C1-C3)alkyl, which is optionally substituted on the cycloalkyl by 1 to 4 substituents independently selected from the group consisting of a fluorine atom, an -OH group, a (C1-C4)alkyl group, a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group and an oxo group;

[0027] ■ 4- to 7-membered heterocycloalkyl containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur, such as tetrahydropyranyl or tetrahydrofuranyl, said heterocycloalkyl being saturated or partially saturated and optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluorine atoms, (C1-C3)alkyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, oxo, (C1-C3)alkoxy and -OH groups;

[0028] ■ (C1-C6) alkyl, such as isobutyl or ethylbutyl, optionally substituted with 1 to 4 substituents independently selected from the group consisting of fluorine atoms, (C1-C3) alkoxy, (C1-C3) fluoroalkoxy and -OH groups; and

[0029] ■phenyl(C1-C2)alkyl, the phenyl being optionally substituted by 1 to 3 substituents independently selected from the group consisting of: halogen atoms; (C1-C3)alkyl; (C1-C3)fluoroalkyl; (C1-C3)alkoxy; (C1-C3)fluoroalkoxy; cyano; and -OH groups;

[0030] -X represents -CH2-, -O- or -S-;

[0031] -Y represents -CH2-, -O- or -NH-;

[0032] - R7 independently represents a (C1-C3)alkyl group such as a methyl group, a halogen atom such as a fluorine atom, a cyano group, or a (C1-C3)fluoroalkyl group such as a trifluoromethyl group;

[0033] -R8 represents a hydrogen atom or a (C1-C3) alkyl group or a cyclopropyl group;

[0034] -n is 0, 1, or 2;

[0035] -m is 0 or 1; and

[0036] -p is 0 or 1.

[0037] Also disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts thereof:

[0038]

[0039] in:

[0040] - R1 and R2 independently represent a hydrogen atom or a deuterium atom;

[0041] -R3 represents a hydrogen atom, a -COOH group or a -OH group;

[0042] - R3′ and R3″ independently represent a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom, or a cyano group;

[0043] -R4 represents a hydrogen atom or a fluorine atom;

[0044] - R5 and R5' independently represent a hydrogen atom or a fluorine atom;

[0045] -R6 represents a group selected from the following:

[0046] ■ phenyl, which is optionally substituted by 1 to 3 substituents independently selected from the group consisting of a halogen atom; a (C1-C6)alkyl group optionally substituted by a cyano group or an -OH group; a (C1-C6)fluoroalkyl group; a (C3-C6)cycloalkyl group; a (C1-C6)alkoxy group; a (C1-C6)fluoroalkoxy group; a cyano group; a trifluoromethylsulfonyl group; a (C1-C4)alkylthio group; a (C1-C4)fluoroalkylthio group; a (C1-C4)alkylsulfonyl group; and an -OH group;

[0047] ■ a fused phenyl group selected from a phenyl group fused to a (C3-C6)cycloalkyl group, the (C3-C6)cycloalkyl ring of which optionally contains unsaturation, and wherein the fused phenyl group is optionally substituted with 1 to 3 substituents independently selected from a (C1-C3)alkyl group, a hydroxyl group, a halogen atom, a (C1-C6)fluoroalkyl group and a (C1-C3)alkoxy group;

[0048] ■ a bicyclic group containing 5 to 12 carbon atoms, optionally containing 1 to 2 degrees of unsaturation; optionally substituted by 1 to 4 substituents independently selected from the group consisting of fluorine atoms, -OH groups, (C1-C3)alkyl groups, (C1-C3)fluoroalkyl groups, (C1-C3)alkoxy groups, (C1-C3)fluoroalkoxy groups and oxo groups;

[0049] ■ a heteroaryl group containing 2 to 9 carbon atoms and containing from 1 to 3 heteroatoms independently selected from oxygen, nitrogen and sulfur and at least 5 atoms including carbon atoms and heteroatoms, such as a pyridyl group, a pyridone group or a pyrrolyl group, the heteroaryl group being optionally substituted by 1 to 3 substituents independently selected from a halogen atom, a (C1-C6)alkyl group, a (C1-C6)fluoroalkyl group, a (C1-C6)alkoxy group, a (C1-C6)fluoroalkoxy group, a cyano group, a carbamoyl group and a -OH group;

[0050] ■ a cycloalkyl group containing 3 to 7 carbon atoms, which is saturated or partially saturated and optionally substituted with 1 to 4 substituents independently selected from:

[0051] o fluorine atom, -OH group, (C1-C3) alkyl group, (C1-C3) fluoroalkyl group, (C1-C3) alkoxy group, (C1-C3) fluoroalkoxy group, oxo group,

[0052] o (C3-C6) cycloalkyl and phenyl, wherein the (C3-C6) cycloalkyl or phenyl is optionally substituted with one or two halogen atoms or (C1-C3) alkyl;

[0053] ■ (C3-C6)cycloalkyl (C1-C3)alkyl, which is optionally substituted on the cycloalkyl by 1 to 4 substituents independently selected from the group consisting of a fluorine atom, an -OH group, a (C1-C4)alkyl group, a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group and an oxo group;

[0054] ■ 4- to 7-membered heterocycloalkyl containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur, such as tetrahydropyranyl or tetrahydrofuranyl, said heterocycloalkyl being saturated or partially saturated and optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluorine atoms, (C1-C3)alkyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, oxo, (C1-C3)alkoxy and -OH groups;

[0055] ■ (C1-C6) alkyl, such as isobutyl or ethylbutyl, optionally substituted with 1 to 4 substituents independently selected from the group consisting of fluorine atoms, (C1-C3) alkoxy, (C1-C3) fluoroalkoxy and -OH groups; and

[0056] ■phenyl(C1-C2)alkyl, the phenyl being optionally substituted by 1 to 3 substituents independently selected from the group consisting of: halogen atoms; (C1-C3)alkyl; (C1-C3)fluoroalkyl; (C1-C3)alkoxy; (C1-C3)fluoroalkoxy; cyano; and -OH groups;

[0057] -X represents -CH2-, -O- or -S-;

[0058] -Y represents -CH2-, -O- or -NH-;

[0059] - R7 independently represents a (C1-C3)alkyl group such as a methyl group, a halogen atom such as a fluorine atom, a cyano group, or a (C1-C3)fluoroalkyl group such as a trifluoromethyl group;

[0060] -R8 represents a hydrogen atom, or a (C1-C3) alkyl group or a cyclopropyl group;

[0061] -n is 0, 1, or 2;

[0062] -m is 0 or 1; and

[0063] -p is 0 or 1;

[0064] Provided that when Y represents -O- or -NH-, and p is 1, then the asymmetric carbon of the pyrrolidine attached to Y has the (R) configuration.

[0065] The compounds of formula (I) may contain one or more asymmetric carbon atoms and may therefore exist in the form of enantiomers.

[0066] The compounds of formula (I) may also exist in tautomeric forms.

[0067] The compound of formula (I) may exist in the form of a base, an acid, a zwitterion or an addition salt with an acid or a base. Accordingly, provided herein is a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0068] These salts may be prepared with pharmaceutically acceptable acids or bases, although salts of other acids or bases useful, for example, in the purification or isolation of compounds of formula (I) are also provided.

[0069] Among suitable salts of the compounds of formula (I), hydrochlorides may be cited.

[0070] As used herein, unless otherwise mentioned throughout this specification, the following terms have the following definitions:

[0071] - halogen atoms: fluorine, chlorine, bromine or iodine atoms, and in particular fluorine and chlorine atoms;

[0072] -Oxo: "=O" group;

[0073] - Alkyl: a straight or branched saturated hydrocarbon aliphatic group, which, unless otherwise specified, contains from 1 to 6 carbon atoms (indicated as "(C1-C6) alkyl"). By way of example, but not limited to: methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl and isohexyl, etc. may be mentioned;

[0074] - Cycloalkyl: saturated or partially unsaturated and unsubstituted or substituted monocyclic alkyl radicals, which, unless otherwise indicated, contain from 3 to 7 carbon atoms. By way of example, but not limited to, mention may be made of: cyclopropyl, cyclobutyl, cyclopentyl, cyclobutenyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, etc., in particular cyclopentyl, cyclohexyl, cycloheptyl, cycloheptenyl or cyclohexenyl;

[0075] - Cycloalkylalkyl: an alkyl group substituted by a cyclic alkyl group as defined above. Mention may be made, but is not limited to: cyclobutylmethyl;

[0076] - Heterocycloalkyl: saturated or partially unsaturated 4 to 7 membered cycloalkyl containing 1 to 2 heteroatoms independently selected from oxygen, nitrogen and sulfur, in particular oxygen or nitrogen. By way of example, but not limited to, mention may be made of: morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, aziridinyl, oxanyl, oxetanyl, tetrahydropyranyl, morpholinyl, tetrahydrofuranyl, oxepanyl, diazepanyl, dioxanyl, tetrahydropyranyl and tetrahydrothiopyranyl. Heterocycloalkyl is advantageously tetrahydrofuranyl or tetrahydropyranyl.

[0077] -Fluoroalkyl: an alkyl group as defined previously, wherein the alkyl group is substituted by at least one fluorine atom. In other words, at least one hydrogen atom of the alkyl group is replaced by a fluorine atom. By way of example, -CH2F, -CHF2, -CH2CHF2, -CH2CH2F, etc. may be mentioned. When all hydrogen atoms belonging to the alkyl group are replaced by fluorine atoms, the fluoroalkyl group may be named as a perfluoroalkyl group. By way of example, trifluoromethyl or trifluoroethyl, etc. may be mentioned;

[0078] - Alkoxy: -O-alkyl, wherein alkyl is as defined previously. By way of example, but not limited to, there may be mentioned: methoxy; ethoxy; propoxy; isopropoxy; linear butoxy, sec-butoxy or tert-butoxy; isobutoxy; pentyloxy or hexyloxy, etc.;

[0079] -Fluoroalkoxy: -O-alkyl, wherein alkyl is as defined previously and wherein alkyl is substituted by at least one fluorine atom. In other words, at least one hydrogen atom of the alkyl is replaced by a fluorine atom. By way of example, -OCH2F, -OCHF2, -OCH2CH2F, etc. may be mentioned. When all hydrogen atoms belonging to the alkyl are replaced by fluorine atoms, the fluoroalkoxy may be named as perfluoroalkoxy. By way of example, trifluoromethoxy, etc. may be mentioned;

[0080] -(C1-C4)alkylthio, which is also named (C1-C4)alkylsulfanyl: -S-alkyl, wherein alkyl is as defined previously. By way of example, but not limited to, there may be mentioned: methylthio, ethylthio, propylthio, isopropylthio, straight-chain secondary or tert-butylthio, isobutylthio, etc.;

[0081] -(C1-C4)alkylsulfonyl: -SO2-alkyl, wherein alkyl is as defined above. For example, -SO2CH3, -SO2CH2CH3, etc. may be mentioned but are not limited thereto;

[0082] -(C1-C4)fluoroalkylthio, which is also named (C1-C4)fluoroalkylsulfanyl: -S-fluoroalkyl, wherein the fluoroalkyl group is as defined above. For example, there can be mentioned but are not limited to: fluoromethylthio, difluoromethylthio, trifluoromethylthio, etc.;

[0083] - Fused phenyl: a bicyclic radical comprising from 7 to 10 carbon atoms and containing a phenyl moiety. The phenyl moiety may be fused to a (C3-C6)cycloalkyl group, i.e. the phenyl moiety may share a bond with the (C3-C6)cycloalkyl group. The fused phenyl group may be bound to the rest of the molecule via its phenyl moiety. It may be substituted. Examples are, but are not limited to, indanyl, bicyclo[4.2.0]octa-1(6),2,4-trienyl, tetrahydronaphthyl, etc.;

[0084] -Heteroaryl: A cyclic 5- to 10-membered aromatic group containing 2 to 9 carbon atoms and 1 to 3 heteroatoms such as nitrogen, oxygen or sulfur. Such nitrogen atoms may be replaced by oxygen atoms to form an -N-O bond. Such -N-O bonds may be in the form of N-oxides (-N + -O - ) in the form of. The heteroaryl group may be monocyclic or bicyclic. As examples of heteroaryl groups, mention may be made, but is not limited to: thiophene, furan, thiadiazole, thiazole, imidazole, pyridazine, triazine, pyrazine, oxadiazole, pyrazole, isothiazole, oxazole, isoxazole, pyridine, pyrimidine, benzotriazole, benzoxazole, pyrrolo[2,3-b]pyridine, benzimidazole, benzooxadiazole, benzothiazole, benzothiadiazole, benzofuran, indole, isoquinoline, indazole, benzisoxazole, benzisothiazole, pyridone groups and the like. Heteroaryl groups are advantageously pyridine, pyrrole, imidazole, pyrazine, furan, thiazole, pyrazole, thiadiazole, pyridazine, pyridone and pyrimidine, and more particularly pyridine, pyridone and pyrrole;

[0085] - Bicyclic radicals generally containing from 5 to 12 carbon atoms are hydrocarbon radicals chosen from radicals containing two rings connected by:

[0086] Single common atom: "spiro bicyclic". Such spiro bicyclic alkyl groups usually contain 5 to 11 carbon atoms and refer to "spiro (C5-C 11 The ring may be saturated or partially unsaturated. Such spiro bicyclic rings may be unsubstituted or substituted, in particular substituted by at least one (C1-C3)alkyl group such as methyl or fluorine. Regarding the definition of R6, as spiro (C5-C 11) Examples of bicyclic rings include, but are not limited to, spiro[2.3]hexane, spiro[3.3]heptane, spiro[3.3]heptene, spiro[2.5]octane and 7-azaspiro[3.5]nonane. Also for the R6 group, spiro(C5-C 11 ) The bicyclic ring is advantageously spiro[3.3]heptane or spiro[3.3]heptene.

[0087] Two common atoms: In this case, the bicyclic group contains 7 to 12 carbon atoms and optionally contains 1 to 2 degrees of unsaturation. As examples of such bicyclic groups, mention may be made, without limitation, of cis-1,3a,4,5,6,6a-hexahydropentalenyl, bicyclo[3.1.0]hex-1-yl, bicyclo[4.1.0]heptanyl and octahydropentalenyl.

[0088] Three or more common atoms: In this case, the bicyclic group contains 6 to 10 carbon atoms and such a bicyclic group may be referred to as a "bridged (C6-C 10 )cycloalkyl", the ring has three or more atoms in total and the bridge contains at least one atom, such as 1, 2 or 3 atoms and preferably 1 atom. As examples of such bridged cycloalkyl groups, mention may be made, but are not limited to, bicyclo[3.2.1]octan-3-yl and bicyclo[2.2.1]hept-2-yl.

[0089] - Zwitterion means: a generally neutral molecule having both positive and negative charges and possessing both acidic and basic groups.

[0090] In another embodiment, in the compounds of formula (I) as defined above, the asymmetric carbon of the pyrrolidine or azetidine attached to Y has the (R) configuration.

[0091] In another embodiment, in the compounds of formula (I) as defined above, R1 and R2 are hydrogen atoms.

[0092] In another embodiment, in the compounds of formula (I) as defined above, R3 is a -COOH group.

[0093] In another embodiment, in the compounds of formula (I) as defined above, R3 is a hydrogen atom.

[0094] In another embodiment, in the compounds of formula (I) as defined above, R3 is a -OH group.

[0095] In another embodiment, in the compounds of formula (I) as defined above, R3′ and R3″ represent a hydrogen atom.

[0096] In another embodiment, in the compounds of formula (I) as defined above, R4 represents a hydrogen atom.

[0097] In another embodiment, in the compound of formula (I) as defined above, X represents -O- or -CH2-, and preferably X represents -CH2-.

[0098] In another embodiment, in the compounds of formula (I) as defined above, X represents -CH2-.

[0099] In another embodiment, in the compounds of formula (I) as defined above, X represents -O-.

[0100] In another embodiment, in the compounds of formula (I) as defined above, R5 and R5' represent a hydrogen atom.

[0101] In another embodiment, in the compound of formula (I) as defined above, R6 represents:

[0102] ■ phenyl, which is optionally substituted by 1 to 3 substituents independently selected from the following: a halogen atom; a (C1-C6)alkyl group optionally substituted by a cyano group or an -OH group; a (C1-C6)fluoroalkyl group; a (C3-C6)cycloalkyl group; a (C1-C6)alkoxy group; a (C1-C6)fluoroalkoxy group; a cyano group; a trifluoromethylsulfonyl group; a (C1-C4)alkylthio group; a (C1-C4)fluoroalkylthio group; a (C1-C4)alkylsulfonyl group; and an -OH group; or

[0103] ■ a cycloalkyl group containing 3 to 7 carbon atoms, which is saturated or partially saturated and optionally substituted with 1 to 4 substituents independently selected from:

[0104] o fluorine atom, -OH group, (C1-C3) alkyl group, (C1-C3) fluoroalkyl group, (C1-C3) alkoxy group, (C1-C3) fluoroalkoxy group, oxo group,

[0105] o (C3-C6)cycloalkyl and phenyl, wherein the (C3-C6)cycloalkyl or phenyl is optionally substituted by one or two halogen atoms or (C1-C3)alkyl.

[0106] In another embodiment, in the compound of formula (I) as defined above, R6 represents a phenyl group, which is optionally substituted by 1 to 3 substituents independently selected from the following: a halogen atom; a (C1-C6)alkyl group optionally substituted by a cyano group or an -OH group; a (C1-C6)fluoroalkyl group; a (C3-C6)cycloalkyl group; a (C1-C6)alkoxy group; a (C1-C6)fluoroalkoxy group; a cyano group; a trifluoromethylsulfonyl group; a (C1-C4)alkylthio group; a (C1-C4)fluoroalkylthio group; a (C1-C4)alkylsulfonyl group; and an -OH group.

[0107] In another embodiment, in the compound of formula (I) as defined above, R6 represents a phenyl group, said phenyl group being optionally substituted with 1 or 2 substituents independently selected from a chlorine atom, a fluorine atom and a methyl group.

[0108] In another embodiment, in the compounds of formula (I) as defined above, R6 represents phenyl.

[0109] In another embodiment, in the compound of formula (I) as defined above, R6 represents a phenyl group substituted by 1 or 2 substituents independently selected from a chlorine atom, a fluorine atom and a methyl group.

[0110] In another embodiment, in the compounds of formula (I) as defined above, R6 represents a cycloalkyl group containing 3 to 7 carbon atoms, which is saturated or partially saturated and optionally substituted with 1 to 4 substituents independently selected from:

[0111] o fluorine atom, -OH group, (C1-C3) alkyl group, (C1-C3) fluoroalkyl group, (C1-C3) alkoxy group, (C1-C3) fluoroalkoxy group, oxo group,

[0112] o (C3-C6)cycloalkyl and phenyl, wherein the (C3-C6)cycloalkyl or phenyl is optionally substituted by one or two halogen atoms or (C1-C3)alkyl.

[0113] In another embodiment, in the compound of formula (I) as defined above, R6 represents a cyclohexyl group substituted by 1 or 2 substituents independently selected from a chlorine atom and a methyl group.

[0114] In another embodiment, in the compounds of formula (I) as defined above, R6 represents cyclopentyl.

[0115] In another embodiment, in the compounds of formula (I) as defined above, R7 represents a methyl group or a fluorine atom and n is 0 or 1.

[0116] In another embodiment, in the compounds of formula (I) as defined above, R8 represents a hydrogen atom or a methyl group.

[0117] In another embodiment, in the compounds of formula (I) as defined above, Y represents -O-.

[0118] In another embodiment, in the compound of formula (I) as defined above, Y represents -O-, and the asymmetric carbon of the pyrrolidine or azetidine attached to -O- has the (R) configuration.

[0119] In another embodiment, in the compound of formula (I) as defined above, Y represents -O-, p is 1, and the asymmetric carbon of the pyrrolidine attached to -O- has the (R) configuration.

[0120] In another embodiment, in the compounds of formula (I) as defined above, Y represents -CH2-.

[0121] In another embodiment, in the compounds of formula (I) as defined above, Y represents -NH-.

[0122] In another embodiment, in the compound of formula (I) as defined above, Y represents -NH-, and the asymmetric carbon of the pyrrolidine or azetidine attached to -NH- has the (R) configuration.

[0123] In another embodiment, in the compound of formula (I) as defined above, Y represents -NH-, p is 1, and the asymmetric carbon of the pyrrolidine attached to -NH- has the (R) configuration.

[0124] In another embodiment, in the compounds of formula (I) as defined above, m is 1.

[0125] In another embodiment, in the compounds of formula (I) as defined above, m is 0.

[0126] In another embodiment, in the compounds of formula (I) as defined above, p is 1.

[0127] In another embodiment, in the compounds of formula (I) as defined above, p is 0.

[0128] In another embodiment, in the compounds of formula (I) as defined above, R3 is a -COOH group and R6 represents a phenyl group, which is optionally substituted by 1 or 2 substituents independently selected from chlorine atoms, fluorine atoms and methyl groups. In this embodiment, R3' and R3" are in particular hydrogen atoms. Also in this embodiment, R1, R2, R4, R5, R5' and R8 are hydrogen atoms. In this embodiment, Y is -O-, p is equal to 1, m is equal to 1 and n is equal to 0. Also in this embodiment, X is a -CH2- group.

[0129] In another embodiment, in the compounds of formula (I) as defined above, R3 is a -COOH group and R6 represents a cyclohexyl group substituted by 1 or 2 substituents independently selected from chlorine atoms and methyl groups. In this embodiment, R3' and R3" are in particular hydrogen atoms. Also in this embodiment, R1, R2, R4, R5, R5' and R8 are hydrogen atoms. In this embodiment, Y is -O-, p is equal to 1, m is equal to 1 and n is equal to 0. Also in this embodiment, X is a -CH2- group.

[0130] In another embodiment, in the compound of formula (I) as defined above, R3 is a -COOH group and R6 is a cyclopentyl group. In this embodiment, R3' and R3" are in particular hydrogen atoms. Also in this embodiment, R1, R2, R4, R5, R5' and R8 are hydrogen atoms. In this embodiment, Y is -O-, p is equal to 1, m is equal to 1 and n is equal to 0. Also in this embodiment, X is a -CH2- group.

[0131] Among the compounds of formula (I) described herein, the following compounds or their pharmaceutically acceptable salts, in particular their hydrochlorides, may be mentioned in particular:

[0132] -(R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (1)

[0133] -(R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-8-phenyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (2)

[0134] -(R)-8-(2-chlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (3)

[0135] -(R)-8-(2-chloro-4-methylphenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (4)

[0136] -(R)-8-(2-chloro-4-fluorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (5)

[0137] -(R)-8-(4-chloro-2-fluorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (6)

[0138] -(R)-8-(2-fluoro-4-methylphenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (7)

[0139] -(R)-8-(2,4-dimethylphenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (8)

[0140] -(R)-8-(2-chloro-3-fluorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (9)

[0141] -(R)-8-(4,4-difluorocyclohexyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, (10)

[0142] -(R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-8-(4-methylcyclohexyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1, (11)

[0143] -(R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-8-(4-methylcyclohexyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 2, (12)

[0144] -(R)-8-(4,4-dimethylcyclohexyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride, (13)

[0145] -(R)-8-cyclopentyl-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (14)

[0146] -(R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-8-phenyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (15)

[0147] -(R)-8-(2-chlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (16)

[0148] -(R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (17)

[0149] -(R)-8-(4-fluoro-2-methylphenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (18)

[0150] -(R)-9-(2-Fluoro-3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-8-phenyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride, (19)

[0151] -(R)-8-(2-chlorophenyl)-9-(2-fluoro-3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride, (20)

[0152] -(R)-8-(2,4-dichlorophenyl)-9-(2-fluoro-3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride, (21)

[0153] -(R)-9-(5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-8-phenyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (22)

[0154] -(R)-8-(2-chlorophenyl)-9-(5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (23)

[0155] -(R)-8-(2-chlorophenyl)-9-(5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (24)

[0156] -(R)-9-(2-Fluoro-5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-8-phenyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride, (25)

[0157] -(R)-8-(2-chlorophenyl)-9-(2-fluoro-5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride, (26)

[0158] -(R)-8-(2,4-dichlorophenyl)-9-(2-fluoro-5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, (27)

[0159] -8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1, (28)

[0160] -8-(2-chlorophenyl)-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, (29)

[0161] -8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, (30)

[0162] -8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (31)

[0163] -8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (32)

[0164] -(R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, (33)

[0165] -(R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol, (34)

[0166] -(R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]oxepin -8-carboxylic acid hydrochloride, (35)

[0167] -8-(3-chlorophenyl)-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1, (36)

[0168] -8-(3-chlorophenyl)-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 2, (37)

[0169] -(R)-3-(3-(8-(2,4-dichlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)phenoxy)-1-(3-fluoropropyl)pyrrolidine, (38)

[0170] -(R)-3-(3-(8-(2-chlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)phenoxy)-1-(3-fluoropropyl)pyrrolidine, (39)

[0171] -(R)-6-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid hydrochloride, (40), and

[0172] -(R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thia -8-ol, (41).

[0173] Another embodiment is a compound selected from the above list or a pharmaceutically acceptable salt thereof for use in therapy, especially as an inhibitor and degrader of estrogen receptors.

[0174] Another embodiment is a compound selected from the above list or a pharmaceutically acceptable salt thereof for use in the treatment of cancer, especially breast cancer.

[0175] Another embodiment is a method of inhibiting and degrading estrogen receptors, which comprises administering a therapeutically effective amount of a compound selected from the above list or a pharmaceutically acceptable salt thereof to a subject, especially a human, in need thereof.

[0176] Another embodiment is a method for treating ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation, comprising administering to a subject, particularly a human, in need thereof a therapeutically effective amount of a compound selected from the above list or a pharmaceutically acceptable salt thereof.

[0177] Another embodiment is a method of treating cancer, comprising administering to a subject, particularly a human, in need thereof a therapeutically effective amount of a compound selected from the above list or a pharmaceutically acceptable salt thereof.

[0178] Another embodiment is a pharmaceutical composition comprising, as an active ingredient, an effective dose of a compound selected from the above list or a pharmaceutically acceptable salt thereof, and also at least one pharmaceutically acceptable excipient.

[0179] The compound of formula (I) can be prepared by the following method.

[0180] Compounds of formula (I) and other related compounds with different substituents are synthesized using techniques and materials described below or otherwise known to those skilled in the art. In addition, the solvents, temperatures and other reaction conditions presented below may be varied as deemed appropriate by those skilled in the art.

[0181] The following general methods for preparing compounds of formula (I) optionally modified by using appropriate reagents and conditions for introducing the various moieties found in formula (I) are described below.

[0182] The following abbreviations and empirical formulas are used:

[0183] Argon

[0184] BOC2O Di-tert-butyl dicarbonate

[0185] CO Carbon monoxide

[0186] Cs2CO3 Cesium carbonate

[0187] DABCO 1,4-diazabicyclo[2.2.2]octane

[0188] DBU 1,8-diazabicyclo[5.4.0]undec-7-ene

[0189] DCM Dichloromethane

[0190] DIEA Diisopropylethylamine

[0191] DMF N,N-Dimethylformamide

[0192] DMAP dimethylaminopyridine

[0193] DMSO Dimethyl sulfoxide

[0194] Et2O Ether

[0195] EtOAc Ethyl acetate

[0196] EtOH

[0197] H2 Hydrogen

[0198] HCl

[0199] HPLC High Performance Liquid Chromatography

[0200] K2CO3 Potassium carbonate

[0201] KHMDS Potassium Hexamethyldisilazane

[0202] KOH Potassium Hydroxide

[0203] LiHMDS Lithium bis(trimethylsilyl)amide

[0204] LiOH Lithium Hydroxide

[0205] MeCN Acetonitrile

[0206] MeOH Methanol

[0207] MeTHF 2-Methyltetrahydrofuran

[0208] MgSO4 Magnesium sulfate

[0209] MTBE Methyl tert-butyl ether

[0210] n-BuLi n-butyllithium

[0211] Na2SO4 Sodium sulfate

[0212] NaH Sodium hydride

[0213] NaHCO3 Sodium bicarbonate

[0214] NaOH Sodium hydroxide

[0215] NH4OH Ammonium Hydroxide

[0216] Pd2(dba)3 tris(dibenzylideneacetone)dipalladium(0)

[0217] Pd / C Palladium / Carbon

[0218] Pd(dppf)Cl2 [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) chloride

[0219] Pd(OAc)2 Palladium acetate

[0220] Pd(PPh3)2Cl2 Bis(triphenylphosphine)palladium(II) dichloride

[0221] PhOK Potassium Phenolate

[0222] PPh3 Triphenylphosphine

[0223] RT Room temperature

[0224] SCX Strong Cation Exchange

[0225] SFC Supercritical Fluid Chromatography

[0226] TEA Triethylamine

[0227] TFA Trifluoroacetic acid

[0228] THF Tetrahydrofuran

[0229] XANTPHOS (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) Scheme 1a - Part-1: Preparation of compounds of formula (I) - General method

[0230] Scheme 1a-Part-2

[0231]

[0232] According to Scheme 1a-Part-1 and Part-2, wherein R3a is a hydrogen atom or a carboxylate such as -COOMe, -COOEt, or a protected -OH such as, for example, O-pivaloyl, and R1, R2, R3, R3', R3", R4, R5, R5', R6, R7, R8, X, m, n, p and Y are as defined above, compound 1A (when X=C, prepared according to WO 2017140669) can be converted to compound 1C in step 1 by treating with compound 1B in the presence of a palladium catalyst such as bis(triphenylphosphine)palladium(II) chloride Pd(PPh3)2Cl2 and a phosphine such as triphenylphosphine in a solution in toluene by heating to solvent reflux in the presence of a base such as KOPh.

[0233] Compound 1C can be converted to compound 1E in step 2 by treating with compound 1D using, for example, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of dioxane and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux in a Suzuki coupling reaction.

[0234] Alternatively, compound 1E can be obtained in step 1′ by Suzuki coupling between compound 1A and compound 1D′ using, for example, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of dioxane and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux.

[0235] Compound IE can be converted to compound IF in step 3 by treatment with pyridinium tribromide, for example in DCM or THF at room temperature.

[0236] Compound 1F can be converted to compound 1H in step 4 by treating with compound 1B in the presence of a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride Pd(PPh3)2Cl2 and a phosphine such as triphenylphosphine in toluene in solution by heating to solvent reflux in the presence of a base such as KOPh or AcOK.

[0237] Compound 1G (wherein R6 is phenyl or heteroaryl) can be prepared in step 5 in a Suzuki coupling reaction between compound 1H and R6Br or R6I or R6OTf using, for example, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of dioxane and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux.

[0238] Compound 1G can also be prepared from compound 1F in step 6 in a Suzuki coupling with a suitable boronic acid reagent R6B(OR')2 (wherein -B(OR')2 is a boronic acid or pinacol ester and R6 is as defined above), using, for example, Pd(dppf)Cl2 complexed with DCM as a catalyst, in a mixture of dioxane and water as solvent and in the presence of a base (e.g. Cs2CO3) at room temperature or by heating to reflux solvent. When R6 is a substituted cycloolefin, heterocycloolefin, it can be reduced by, for example, hydrogenation with a catalyst such as Pd / C at a temperature up to 70°C under a hydrogen pressure (H2) of about 5 bar to give the corresponding saturated compound 1G.

[0239] Alternatively, compound 1F can be subjected to a photocatalytic coupling reaction with R6Br (wherein R6 is alkyl, cycloalkyl or spirobicycloalkyl as defined above) using a catalyst such as (Ir[dF(CF3)ppy]2(dtbpy))PF6 and nickel(II) chloride ethylene glycol dimethyl ether complex in the presence of tris(trimethylsilyl)silane and a base such as 4,4'-di-tert-butyl-2,2'-bipyridine and sodium carbonate to give the corresponding compound 1G.

[0240] Compound 1G can be converted to a compound of formula (I) in step 7 in the presence of a hydroxide ion source such as NaOH or LiOH in solution in methanol (MeOH).

[0241] Compound 1F can be converted to a compound of formula 1Fa in step 8 in the presence of a hydroxide ion source such as NaOH or LiOH in solution in methanol (MeOH).

[0242] The compound 1Fa can be converted to a compound of formula (I) in step 9 by Suzuki conditions using a suitable boronic acid reagent R6B(OR')2 (wherein -B(OR')2 is a boronic acid or pinacol ester and R6 is as defined above), using, for example, Pd(dppf)Cl2 complexed with DCM as a catalyst, in a mixture of dioxane and water as solvent and in the presence of a base (e.g. Cs2CO3), at room temperature or by heating to reflux of the solvent. When R6 is a substituted cycloolefin, heterocycloolefin, it can be reduced by, for example, hydrogenation with a catalyst such as Pd / C at a temperature of up to 70°C under a hydrogen (H2) pressure of about 5 bar to give the corresponding saturated compound of formula (I).

[0243] When R3a is -COOMe, -COOEt, or protected -OH such as O-pivaloyl, deprotection can be carried out in step 7 by treating with an aqueous solution of sodium hydroxide (NaOH) 2N or lithium hydroxide (LiOH) in methanol (MeOH). When R3 is -COOH, extraction of the product can obtain the sodium or lithium salt of the compound of formula (I). Acidification to pH 6-7 with an aqueous solution of HCl 2N can obtain the neutral form of the compound of formula (I). Acidification to pH 1-2 with an aqueous solution of HCl 2N can obtain the hydrochloride of the compound of formula (I). Purification using HPLC in the presence of formic acid or trifluoroacetic acid in the eluent can obtain the formate or trifluoroacetate of the compound of formula (I).

[0244] Option 1b : Alternative method for preparing compound 1E

[0245]

[0246] According to Scheme 1b, wherein R3a is a hydrogen atom or a carboxylate such as -COOMe, -COOEt, or a protected -OH such as, for example, O-pivaloyl, R1, R2, R3a, R3', R3", R4, R5, R5', R7, R8, X, m, n and p are as defined above and Y is -O-, compound 1A (when X=C, prepared according to WO 2017140669) can be converted in step 1 to compound 1J by, for example, treating with compound 1D" using a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride Pd(PPh3)2Cl2 in a mixture of dioxane and water as solvent and in the presence of a base such as cesium carbonate (Cs2CO3) at room temperature or by heating to solvent reflux.

[0247] Compound 1J can be converted to compound 1E (Y = -O-) in step 2 by reaction with compound 1K (A = -Br or -I) in the presence of a base such as cesium carbonate (Cs2CO3) in DMF or MeCN, or when (A = -OH) under Mitsunobu conditions using, for example, N,N,N',N'-tetramethylazodicarbonamide and triphenylphosphine as coupling agents in THF as solvent.

[0248] Solution 1c : Alternative method for preparing compound 1G

[0249]

[0250] According to Scheme 1c, wherein R3a is a hydrogen atom or a carboxylate such as -COOMe, -COOEt, or a protected -OH such as, for example, O-pivaloyl, R1, R2, R3a, R3', R3", R4, R5, R5', R7, R8, X, Y, m, n and p are as defined above, and R6 is phenyl or heteroaryl, compound 1L can be prepared in step 1 by treating with aryl and heteroaryl bromides or iodides in the presence of a palladium catalyst such as tris(dibenzylidene) In the presence of ((9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (XANTPHOS) in toluene, the compound 1M is converted to 1M by heating to solvent reflux in the presence of a base such as KCO or CsCO. An alternative way to prepare compound 1M, wherein R6 can be any group as defined above for R6 in formula (I), is described in Scheme 1f below.

[0251] Compound 1M can be converted to compound 1A' in step 2 by treatment with N,N-bis(trifluoromethylsulfonyl)aniline in the presence of a base such as DBU or NaH, or KHMDS in a solvent such as MeTHF at -50 °C.

[0252] Compound 1A' can be converted to compound 1C' in step 3 by treating compound 1B with a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride Pd(PPh3)2Cl2 and a phosphine such as triphenylphosphine in toluene by heating to solvent reflux in the presence of a base such as KOPh.

[0253] Compound 1G can be prepared in a Suzuki coupling reaction between compounds 1C′ and 1D in step 4 or between compounds 1A′ and 1D′ in step 5, using, for example, [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst, in a mixture of dioxane and water and in the presence of a base (e.g., Cs2CO3) by heating to solvent reflux.

[0254] Scheme 1d : Preparation of compounds of formula (I) - General method

[0255]

[0256] According to Scheme 1d, wherein R3a is a hydrogen atom or a carboxylate such as -COOMe, -COOEt, or a protected -OH such as, for example, O-pivaloyl, R1, R2, R3, R3', R3", R4, R5, R5', R6, R7, R8, X, m, n and p are as defined above and Y is -NH-, compound 1A' can be converted in step 1 to compound 1J' by treating with compound 1D" using, for example, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst in a mixture of dioxane and water and in the presence of a base (e.g. Cs2CO3) by heating to solvent reflux.

[0257] Compound 1J' can be converted to compound 1N in step 2 by treatment with trifluoromethanesulfonic anhydride in the presence of pyridine in DCM.

[0258] Compound 1N can be converted to compound 1P in step 3 under Buchwald coupling conditions with compound 1O in microwave at 130° C. in dioxane using, for example, xanthene and Pd(OAc) 2 as the catalytic system.

[0259] Compound 1P can be converted to compound 1Q in step 4 by treatment with TFA in DCM.

[0260] Compound 1Q can be converted to compound 1G in step 5 by treatment with compound 1R (wherein W is Br, I or OSO2R, where R = CH3, PhMe, CF3 or CF2CF2CF2CF3) in the presence of a base such as K2CO3 at 70°C in DMF, or in the presence of NaOH or KOH at room temperature in THF, or in the presence of aqueous NaOH at room temperature in DCM.

[0261] When R3a is -COOMe, -COOEt or protected -OH such as O-pivaloyl, deprotection can be carried out in step 6 by treating with an aqueous solution of NaOH 2N or LiOH in MeOH. When R3 is -COOH, extraction of the product can obtain the sodium or lithium salt of the compound of formula (I). Acidification to pH 6-7 with an aqueous solution of HCl 2N can obtain the neutral form of the compound of formula (I). Acidification to pH 1-2 with an aqueous solution of HCl 2N can obtain the hydrochloride of the compound of formula (I). Using HPLC purification in the presence of formic acid or trifluoroacetic acid in the eluent can obtain the formate or trifluoroacetate of the compound of formula (I).

[0262] Option 1e : Preparation of compounds of formula (1A) (wherein R3a = CO2Me) - General method

[0263]

[0264] According to Scheme 1e, wherein X, m, R3′, R3″ and R8 are defined as described above, compound 1A can be prepared as follows: Compound 1Aa (commercially available or prepared according to WO 2017140669 and WO 2018091153) can be converted to compound 1Ab in step 1 by treatment with trifluoromethanesulfonic anhydride in a solution in DCM in the presence of pyridine as a base.

[0265] Compound 1Ab can be converted to compound 1Ac in step 2 by carbonylation with carbon monoxide in the presence of a palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complexed with DCM (Pd(dppf)Cl 2 ) in a solution in DMF and MeOH.

[0266] Compound 1Ac can be converted to compound 1A in step 3, where R3a = CO2Me, by treatment with trifluoromethanesulfonic anhydride in solution in DCM in the presence of pyridine as base.

[0267] Scheme 1f : Alternative preparation of compounds of formula (1M) - General method

[0268]

[0269] According to Scheme 1f, wherein R3a is a hydrogen atom, a carboxylate such as COOMe, COOEt, or a protected OH such as, for example, O-pivaloyl, and R3′, R3″, R8, R6, X and m are as defined above, compound 1M can alternatively be prepared as follows: Compound 1L can be converted to compound 1La in step 1 by treatment with pyridinium tribromide, for example in DCM or THF at room temperature.

[0270] Compound 1La can be converted to compound 1Lb in step 2 by deprotonation with a base such as LiHMDS in THF followed by treatment with acetic anhydride.

[0271] Compound 1Lc can be prepared in step 3 in a Suzuki coupling reaction between compound 1Lb and R6B(OR')2 or R6BF3K, using, for example, [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) complexed with DCM as a catalyst, in a mixture of toluene and water and in the presence of a base such as cesium carbonate (Cs2CO3) by heating to solvent reflux.

[0272] Compound 1Lc can be converted to compound 1M in step 4, for example, by hydrolysis with aqueous HCl by heating in methanol and DCM.

[0273] Also provided herein is a process for preparing a compound of formula (I) as defined above, wherein a compound of formula 1G:

[0274]

[0275] -- wherein R1, R2, R3', R3", R4, R5, R5', R6, R7, R8, m, n, p, X and Y are as defined above, and R3a is a hydrogen atom or a carboxylate such as -COOMe, -COOEt, or a protected OH such as, for example, O-pivaloyl -- is converted to a compound of formula (I) in the presence of a hydroxide ion source such as NaOH or LiOH in solution in methanol, said step optionally being preceded by a step for obtaining compound 1G, wherein a compound of formula 1F:

[0276]

[0277] -- wherein R1, R2, R3', R3", R4, R5, R5', R7, R8, m, n, p, X and Y are as described above and R3a is as defined above--

[0278] Subjected to Suzuki coupling with a boronic acid reagent R6B(OR')2 (wherein -B(OR')2 is a boronic acid or pinacol ester and R6 is as defined above).

[0279] Also provided herein is a process for preparing a compound of formula (I) as described above, wherein a compound of formula 1Fa:

[0280]

[0281] - wherein R1, R2, R3, R3', R3", R4, R5, R5', R7, R8, m, n, p, X and Y are as described above - undergoes a Suzuki coupling with a boronic acid reagent R6B(OR')2 - wherein -B(OR')2 is a boronic acid or a pinacol ester and R6 is defined above, said step optionally being preceded by a step for obtaining compound 1Fa, wherein a compound of formula 1F:

[0282]

[0283] -- wherein R1, R2, R3', R3", R4, R5, R5', R7, R8, m, n, p, X and Y are as described above, and R3a is a hydrogen atom or a carboxylate such as -COOMe, -COOEt, or a protected -OH such as O-pivaloyl--

[0284] The conversion to compound 1Fa is carried out in solution in methanol in the presence of a hydroxide ion source such as NaOH or LiOH.

[0285] Also provided herein are intermediate compounds selected from the compounds of Formula 1E, 1F, 1G and 1Fa or any pharmaceutically acceptable salt thereof:

[0286]

[0287]

[0288] wherein R1, R2, R3, R3', R3", R4, R5, R5', R6, R7, R8, m, n, p, X and Y are as defined above, and R3a is a hydrogen atom or a carboxylate such as -COOMe, -COOEt, or a protected -OH such as O-pivaloyl.

[0289] Further provided herein are intermediate compounds of Formula 1D' or any pharmaceutically acceptable salt thereof:

[0290]

[0291] wherein R1, R2, R4, R5, R5', R7, Y, p and n are as described above.

[0292] The present application also describes an intermediate compound of Formula 1C' or any pharmaceutically acceptable salt thereof:

[0293]

[0294] wherein R3a, R3′, R3″, X, m, R6 and R8 are as described above.

[0295] In another aspect, there is also provided herein a process for preparing a compound of formula (I) wherein R3 is a -COOH group, comprising a deprotection step of a compound of formula 1G as defined above, optionally followed by a purification step.

[0296] The purification step may, for example, consist of an acidification step (eg with aqueous hydrochloric acid) as shown in step 2 of Example 1 herein below.

[0297] At 400 and 500MHz 1 H NMR spectra were performed on Bruker Avance DRX-400 and Bruker Avance DPX-500 spectrometers, respectively, with chemical shifts (δ, in ppm) in the solvent dimethyl sulfoxide-d6 (d6-DMSO) referenced to 2.5 ppm at a temperature of 303 K. Coupling constants (J) are given in Hertz.

[0298] Liquid chromatography / mass spectrometry (LC / MS) was obtained on a UPLC Acquity Waters instrument using UV detection DAD 210-400 nm and fast Acquity UPLC CSH C18 1.7 μm, size 2.1 x 30 mm, mobile phase H2O+0.1% HCO2H / CH3CN+0.1% HCO2H, light scattering detector Sedere and SQD Waters mass spectrometer.

[0299] Table 1a : (the first column "Example" corresponds to the compound and example number)

[0300]

[0301]

[0302]

[0303]

[0304]

[0305]

[0306]

[0307]

[0308] Table 1b :

[0309]

[0310]

[0311]

[0312]

[0313]

[0314]

[0315]

[0316]

[0317]

[0318]

[0319]

[0320] The following examples describe the preparation of some of the compounds of formula (I) described herein. The quantities of the compounds exemplified below match those given in Tables 1a and 1b above. Unless otherwise specified, all reactions were carried out under an inert atmosphere.

[0321] In the following examples, when the origin of the starting product is not specified, it is understood that the product is a known compound.

[0322] Intermediates:

[0323] Intermediate 1: (R)-1-(3-fluoropropyl)-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrrolidine

[0324]

[0325] Step 1: (R)-tert-butyl 3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine-1-carboxylate

[0326]

[0327] To a mixture of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (1.01 g, 4.50 mmol), (S)-1-N-boc-3-hydroxypyrrolidine (0.97 g, 5.08 mmol) and N,N,N',N'-tetramethylazodicarbonamide (1.25 g, 7.11 mmol) in THF (20 ml) was added PPh3 (1.84 g, 6.87 mmol). The reaction mixture was stirred at room temperature for 18 hours. Isopropyl ether (50 ml) and water (30 ml) were added. The organic phase was washed with water (50 ml), dried over Na2SO4, filtered and concentrated under reduced pressure, and the residue obtained was eluted by flash chromatography with heptane / EtOAc: 80 / 20 to give 1.36 g (78%) of (R)-tert-butyl 3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine-1-carboxylate.

[0328] LC / MS(m / z,MH+):390

[0329] Step 2: (R)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine, hydrochloride

[0330]

[0331] To a solution of (R)-tert-butyl 3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine-1-carboxylate (1.03, 2.65 mmol) in MeOH (10 ml) cooled at 5°C was added HCl 4M in dioxane (5.2 ml, 20.80 mmol). The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure and the obtained residue was triturated with isopropyl ether. The solid was filtered and dried to give 0.76 g (99%) of (R)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine, hydrochloride.

[0332] LC / MS(m / z,MH+):290

[0333] Step 3: (R)-1-(3-fluoropropyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine

[0334]

[0335] A mixture of (R)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine, hydrochloride (0.75 g, 2.62 mmol), KCO (0.73 g, 5.24 mmol), 1-fluoro-3-iodo-propane (0.475 g, 2.48 mmol) in MeCN (7 ml) was heated at 70° C. for 2 hours. After cooling to room temperature, DCM (20 ml) and water (10 ml) were added. The organic phase was washed with Na2SO4, filtered and concentrated under reduced pressure, and the residue obtained was purified by flash chromatography eluting with DCM / MeOH: 95 / 05 to give 0.4 g (44%) of (R)-1-(3-fluoropropyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine.

[0336] LC / MS(m / z,MH+):350

[0337] Intermediate 2: (R)-8-bromo-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0338]

[0339] Step 1: 9-(3-Hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0340]

[0341] A mixture of 9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (25 g, 71.37 mmol) (prepared according to WO 2017140669), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol (17.28 g, 78.50 mmol), Cs2CO3 (46.55 g, 142.73 mmol), Pd(dppf)Cl2 (4.70 g, 6.42 mmol) complexed with DCM in dioxane (204 ml) and water (72 ml) was stirred at room temperature for 30 minutes. The reaction mixture was quenched by adding water (500 ml) and extracted with EtOAc (2×500 ml). The organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure, and the residue obtained was eluted by flash chromatography with heptane / EtOAc: 80 / 20 to give 20.5 g (98%) of methyl 9-(3-hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0342] LC / MS(m / z,MH+):295

[0343] Step 2: (R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0344]

[0345] Method 1

[0346] PPh3 (0.59 g, 2.21 mmol) was added to a mixture of 9-(3-hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (0.5 g, 1.70 mmol), (S)-1-(3-fluoropropyl)pyrrolidin-3-ol (0.276 g, 1.88 mmol) (prepared according to WO 2018091153) and N,N,N',N'-tetramethylazodicarbonamide (0.39 g, 2.23 mmol) in THF (5 ml). The reaction mixture was stirred at room temperature for 18 hours. Isopropyl ether (20 ml) and water (5 ml) were added. The organic phase was washed with water (50 ml), dried over Na2SO4, filtered and concentrated under reduced pressure to give 0.86 g (crude) of (R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, which was used as is in the next step.

[0347] LC / MS(m / z,MH+):424

[0348] Method 2

[0349] A mixture of methyl 9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (0.72 g, 2.06 mmol) (prepared according to WO 2017140669), (R)-1-(3-fluoropropyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine (Intermediate 1) (0.63 g, 1.79 mmol), Cs2CO3 (1.55 g, 4.66 mmol), Pd(dppf)Cl2 (91 mg, 0.1 mmol) complexed with DCM in dioxane (8 ml) and water (2 ml) was stirred at room temperature for 20 minutes. The reaction mixture was quenched by adding water (5 ml) and DCM (10 ml) and extracted with a hydrophobic column. The organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure, and the residue obtained was eluted by flash chromatography with DCM / MeOH: 95 / 05 to give 0.75 g (99%) of (R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0350] Step 3: (R)-8-bromo-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0351]

[0352] To a mixture of (R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (0.75 g, 1.77 mmol) in DCM (8 ml) was added pyridinium tribromide (0.69 g, 1.95 mmol). The reaction mixture was stirred at room temperature for 1.5 hours. The reaction was quenched with a concentrated solution of NaHCO and extracted with a hydrophobic column. The organic phase was dried over Na2SO4, filtered, concentrated under reduced pressure and the obtained residue was purified by flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 90 / 10 to give 0.48 g (54%) of (R)-8-bromo-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0353] LC / MS(m / z,MH+):502

[0354] Intermediate 3: (R)-8-bromo-9-(2-fluoro-5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0355]

[0356] Step 1: 9-(2-Fluoro-5-hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0357]

[0358] Intermediate 3, step 1 was prepared according to a procedure similar to that for the preparation of Intermediate 2, step 1 from methyl 9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (prepared according to WO 2017140669) and 2-fluoro-5-hydroxyphenylboronic acid to give 1.52 g (85%) of methyl 9-(2-fluoro-5-hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0359] LC / MS(m / z,MH+):313

[0360] Step 2: (R)-9-(2-fluoro-5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0361]

[0362] Step 2 of Intermediate 3 was prepared according to a procedure similar to that of Step 2 of Method 1 for the preparation of Intermediate 2 from methyl 9-(2-fluoro-5-hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate and (S)-1-(3-fluoropropyl)pyrrolidin-3-ol (prepared according to WO 2018091153) to give 0.7 g (99%) of methyl (R)-9-(2-fluoro-5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0363] LC / MS(m / z,MH+):442

[0364] Step 3: (R)-8-bromo-9-(2-fluoro-5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0365]

[0366] Intermediate 3, Step 3 was prepared following a procedure analogous to that used to prepare Intermediate 2, Step 3 from (R)-9-(2-fluoro-5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester to afford 0.36 g (42%) of (R)-8-bromo-9-(2-fluoro-5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0367] LC / MS(m / z,MH+):520

[0368] Intermediate 4: (R)-8-bromo-9-(5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0369]

[0370] Step 1: 9-(5-Hydroxy-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0371]

[0372] Intermediate 4, Step 1 was prepared according to a procedure similar to that for the preparation of Intermediate 2, Step 1 from methyl 9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (prepared according to WO 2017140669) and 4-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol to give 1.43 g (81%) of methyl 9-(5-hydroxy-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0373] LC / MS(m / z,MH+):309

[0374] Step 2: (R)-9-(5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0375]

[0376] Step 2 of Intermediate 4 was prepared according to a procedure similar to that of Step 2 of Method 1 for the preparation of Intermediate 2 from methyl 9-(5-hydroxy-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate and (S)-1-(3-fluoropropyl)pyrrolidin-3-ol (prepared according to WO 2018091153) to give 0.7 g (99%) of methyl (R)-9-(5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0377] LC / MS(m / z,MH+):438

[0378] Step 3: (R)-8-bromo-9-(5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0379]

[0380] Step 3 of Intermediate 4 was prepared following a procedure analogous to that of Step 3 of Intermediate 2 from (R)-9-(5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester to afford 0.34 g (41%) of (R)-8-bromo-9-(5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0381] LC / MS(m / z,MH+):516

[0382] Intermediate 5: (R)-8-bromo-9-(2-fluoro-3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0383]

[0384] Step 1: 9-(2-Fluoro-3-hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0385]

[0386] Step 1 of Intermediate 5 was prepared according to a procedure similar to that for Step 1 of Intermediate 2 from methyl 9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (prepared according to WO 2017140669) and 2-fluoro-3-hydroxyphenylboronic acid to give 1.15 g (86%) of methyl 9-(2-fluoro-3-hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0387] LC / MS(m / z,MH+):313

[0388] Step 2: (R)-9-(2-fluoro-3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0389]

[0390] Step 2 of Intermediate 5 was prepared according to a procedure similar to that of Step 2 of Method 1 for the preparation of Intermediate 2 from methyl 9-(2-fluoro-3-hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate and (S)-1-(3-fluoropropyl)pyrrolidin-3-ol (prepared according to WO 2018091153) to give 1.5 g (92%) of methyl (R)-9-(2-fluoro-3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0391] LC / MS(m / z,MH+):442

[0392] Step 3: (R)-8-Bromo-9-(2-fluoro-3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0393]

[0394] Step 3 of Intermediate 5 was prepared following a procedure analogous to that of Step 3 of Intermediate 2 from (R)-methyl 9-(2-fluoro-5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate to afford 0.4 g (23%) of methyl (R)-8-bromo-9-(2-fluoro-3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0395] LC / MS(m / z,MH+):520

[0396] Intermediate 6: (R)-8-bromo-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0397]

[0398] Step 1: 9-(3-Hydroxy-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0399]

[0400] Step 1 of Intermediate 6 was prepared according to a procedure similar to that for Step 1 of Intermediate 2 from methyl 9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (prepared according to WO 2017140669) and 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol to give 1.15 g (87%) of methyl 9-(3-hydroxy-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0401] LC / MS(m / z,MH+):309

[0402] Step 2: (R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0403]

[0404] Step 2 of Intermediate 6 was prepared according to a procedure similar to that of Step 2 of Method 1 for the preparation of Intermediate 2 from methyl 9-(5-hydroxy-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate and (S)-1-(3-fluoropropyl)pyrrolidin-3-ol (prepared according to WO 2018091153) to give 1.5 g (92%) of methyl (R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0405] LC / MS(m / z,MH+):438

[0406] Step 3: (R)-8-bromo-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0407]

[0408] Step 3 of Intermediate 6 was prepared following a procedure analogous to that of Step 3 of Intermediate 2 from (R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester to afford 0.58 g (38%) of (R)-8-bromo-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0409] LC / MS(m / z,MH+):516

[0410] Intermediate 7: 8-bromo-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0411]

[0412] Step 1: tert-Butyl 3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)azetidine-1-carboxylate

[0413]

[0414] CsCO (38.53 g, 118.14 mmol) was added to a mixture of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)phenol (13 g, 59.07 mmol), 1-boc-3-iodoazetidine (25.86 g, 88.61 mmol), DMF (150 ml). The reaction mixture was stirred at 65 ° C for 20 hours. After cooling to room temperature, the reaction mixture was poured into water (1500 ml) and EtOAc (500 ml). The organic phase was dried over NaSO, filtered and concentrated under reduced pressure and the obtained residue was ground with isopropyl ether. The solid was filtered and dried to give 10.6 g (48%) of tert-butyl 3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)azetidine-1-carboxylate.

[0415] LC / MS(m / z,MH+):376

[0416] Step 2: (R)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine, hydrochloride

[0417]

[0418] Step 2 of Intermediate 7 was prepared from tert-butyl 3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)azetidine-1-carboxylate following a procedure similar to that for the preparation of Step 2 of Intermediate 1 to give 9.1 g (crude) of tert-butyl 3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)azetidine-1-carboxylate.

[0419] LC / MS(m / z,MH+):276

[0420] Step 3: 1-(3-fluoropropyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)azetidine

[0421]

[0422] Step 3 of Intermediate 7 was prepared following a procedure similar to that for the preparation of Step 3 of Intermediate 1 from tert-butyl 3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)azetidine-1-carboxylate hydrochloride to give 1.53 g (16%) of 1-(3-fluoropropyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)azetidine.

[0423] LC / MS(m / z,MH+):336

[0424] Step 4: 9-(3-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0425]

[0426] Step 4 of Intermediate 7 was prepared following a procedure analogous to that of Step 1 of Intermediate 2 from methyl 9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (prepared according to WO2017140669) and 1-(3-fluoropropyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)azetidine to afford 0.57 g (94%) of methyl 9-(3-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0427] LC / MS(m / z,MH+):410

[0428] Step 5: 8-bromo-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0429]

[0430] Step 5 of Intermediate 7 was prepared from methyl 9-(3-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate following a procedure analogous to that used to prepare Step 3 of Intermediate 2 to afford 0.56 g (82%) of methyl 8-bromo-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0431] LC / MS(m / z,MH+):488

[0432] Intermediate 8: 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0433]

[0434] A mixture of 9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (15 g, 42.82 mmol) (prepared according to WO 2017140669) in toluene (150 ml), Pd(PPh3)2Cl2 (1.53 g, 2.14 mmol), PPh3 (673.87 mg, 2.57 mmol), bis(pinacolato)diboron (13.38 g, 52.67 mmol) and PhOK (8.04 g, 60.80 mmol) was heated to 75 °C for 1.5 h. The yellow suspension turned orange and then brown. After cooling to room temperature, DCM (150 mL) and water (150 mL) were added and decanted through a hydrophobic column. The organic phase was concentrated under reduced pressure. The residue obtained was purified by flash chromatography eluting with a gradient of heptane / DCM from 85 / 15 to 20 / 80 to give 10.1 g (72%) of methyl 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate as a white solid.

[0435] LC / MS(m / z,MH+):329

[0436] Intermediate 9: 8-(2,4-dichlorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0437]

[0438] Intermediate 9 was prepared from 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (prepared according to WO2020 / 049153) according to a procedure similar to that for the preparation of Intermediate 8 to give 3.9 g (82%) of 8-(2,4-dichlorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester as a white solid.

[0439] LC / MS(m / z,MH+):473

[0440] Intermediate 10: 8-bromo-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0441]

[0442] Step 1: 3-(3-bromobenzyl)-1-(3-fluoropropyl)azetidine

[0443]

[0444] Intermediate 10, step 1 was prepared following a procedure similar to that of Intermediate 1, step 3 from 3-(3-bromophenyl)azetidine, 2,2,2-trifluoroacetate to give 1.4 g (33%) of 3-(3-bromobenzyl)-1-(3-fluoropropyl)azetidine.

[0445] LC / MS(m / z,MH+):286

[0446] Step 2: 9-(3-((1-(3-fluoropropyl)azetidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0447]

[0448] A mixture of 9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (0.62 g, 1.89 mmol) (Intermediate 8), 3-(3-bromobenzyl)-1-(3-fluoropropyl)azetidine (0.59 g, 1.87 mmol), Cs2CO3 (1.83 g, 5.61 mmol), Pd(dppf)Cl2 complexed with DCM (86 mg, 0.11 mmol) in dioxane (6 ml) and water (2.5 ml) was heated to 65° C. for 1 hour. After cooling to room temperature, DCM (10 ml) and water (5 ml) were added. After decantation on a hydrophobic column, the organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure, and the residue obtained was purified by flash chromatography eluting with DCM / MeOH: 95 / 05 to give 0.67 g (88%) of methyl 9-(3-((1-(3-fluoropropyl)azetidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0449] LC / MS(m / z,MH+):408

[0450] Step 3: 8-Bromo-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0451]

[0452] Step 3 of Intermediate 10 was prepared following a procedure analogous to that used to prepare Step 3 of Intermediate 2 from methyl 9-(3-((1-(3-fluoropropyl)azetidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate to afford 0.66 g (83%) of methyl 8-bromo-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0453] LC / MS(m / z,MH+):488

[0454] Intermediate 11: 3-[(3-bromophenyl)methyl]-1-(3-fluoropropyl)pyrrolidine, isomer 1

[0455]

[0456] Step 1: tert-Butyl 3-[(3-bromophenyl)methyl]pyrrolidine-1-carboxylate, Isomer 1 and Isomer 2

[0457]

[0458] At room temperature, DMAP (2.95g, 24.2mmol) and BOC2O (55.4g, 254mmol) were added to a solution of 3-[(3-bromophenyl) methyl] pyrrolidine racemic mixture (58.0g, 242mmol) and TEA (48.9g, 483mmol) in DCM (420ml). The reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was quenched and extracted with DCM (100mL) by adding water (300mL). The organic phase was washed with saline (200mL), dried over Na2SO4, filtered, concentrated under reduced pressure, and the obtained residue was purified by flash chromatography with a gradient elution of petroleum ether / EtOAc from 98 / 02 to 50 / 50 to obtain 45g (51%) of 3-[(3-bromophenyl) methyl] pyrrolidine-1-tert-butyl formate, a racemic mixture.

[0459] The racemic mixture of tert-butyl 3-[(3-bromophenyl)methyl]pyrrolidine-1-carboxylate was separated by preparative SFC (column: DAICEL CHIRALCEL OJ (250×50 mm, 10 μm); supercritical CO2 85% / EtOH [0.1% NH4OH] 15%) to give 19 g of tert-butyl 3-[(3-bromophenyl)methyl]pyrrolidine-1-carboxylate isomer 1 and 19 g of tert-butyl 3-[(3-bromophenyl)methyl]pyrrolidine-1-carboxylate isomer 2.

[0460] LC / MS(m / z,MH+):340

[0461] Step 2: 3-[(3-Bromophenyl)methyl]pyrrolidine, hydrochloride salt isomer 1

[0462]

[0463] Intermediate 11, step 2 was prepared from tert-butyl 3-[(3-bromophenyl)methyl]pyrrolidine-1-carboxylate isomer 1 following a procedure similar to that for the preparation of Intermediate 1, step 2 to give 17 g (crude) of 3-[(3-bromophenyl)methyl]pyrrolidine, hydrochloride salt isomer 1.

[0464] LC / MS(m / z,MH+):240

[0465] Step 3: 3-[(3-bromophenyl)methyl]-1-(3-fluoropropyl)pyrrolidine, Isomer 1

[0466]

[0467] Step 3 of Intermediate 11 was prepared from 3-[(3-bromophenyl)methyl]pyrrolidine, hydrochloride salt Isomer 1 following a procedure analogous to that of Step 3 of Intermediate 1 to afford 10.1 g (74%) of 3-[(3-bromophenyl)methyl]-1-(3-fluoropropyl)pyrrolidine, Isomer 1.

[0468] LC / MS(m / z,MH+):300

[0469] Intermediate 12: 8-(2,4-dichlorophenyl)-9-(3-(((trifluoromethyl)sulfonyl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0470]

[0471] Step 1: 8-(2,4-dichlorophenyl)-9-(3-hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0472]

[0473] Step 1 of Intermediate 12 was prepared from 3-hydroxyphenylboronic acid and methyl 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (prepared according to WO 2020 / 049153) according to a procedure similar to that for the preparation of step 1 of Intermediate 2 to give 2.29 g (86%) of methyl 8-(2,4-dichlorophenyl)-9-(3-hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0474] LC / MS(m / z,MH+):439

[0475] Step 2: 8-(2,4-dichlorophenyl)-9-(3-(((trifluoromethyl)sulfonyl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0476]

[0477] To a mixture of 8-(2,4-dichlorophenyl)-9-(3-hydroxyphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (0.32 g, 0.73 mol) and pyridine (0.12 g, 1.46 mmol) in DCM (5 ml) cooled at 5°C was added trifluoromethanesulfonic anhydride (0.42 g, 1.49 mmol). The reaction mixture was stirred at 5°C for 1 hour. After adding cold water (5 ml) and decanting on a hydrophobic column, the organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure to give 0.48 g (crude) of 8-(2,4-dichlorophenyl)-9-(3-(((trifluoromethyl)sulfonyl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0478] LC / MS(m / z,MH+):571

[0479] Intermediate 13: 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-yl pivalate

[0480]

[0481] Step 1: 6-(2,4-dichlorophenyl)-2-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one

[0482]

[0483] A mixture of 1-bromo-2,4-dichloro-benzene (890 mg, 3.94 mmol), 2-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one (500 m, 2.63 mmol), CsCO (2.03 g, 10.5 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (0.304 g, 0.53 mmol) and tri(dibenzylideneacetone)dipalladium(0) (0.3 g, 0.53 mmol) in xylene (10 ml) was heated to reflux for 16 hours. After cooling to room temperature, water (50 ml) and EtO (50 ml) were added. The organic phase was dried over MgSO, filtered and concentrated under reduced pressure. The residue obtained was purified by flash chromatography eluting with a gradient of cyclohexane / EtOAc from 100 / 00 to 95 / 05 to give 470 mg (42%) of 6-(2,4-dichlorophenyl)-2-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-one.

[0484] LC / MS(m / z,MH+):335

[0485] Step 2: 6-(2,4-dichlorophenyl)-2-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one

[0486]

[0487] A mixture of 6-(2,4-dichlorophenyl)-2-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one (470mg, 1.23mmol) and aluminum chloride (395mg, 2.96mmol) in toluene (8ml) was heated at 90°C for 2 hours. After cooling to room temperature, water (20ml) and EtOAc (50ml) were added. The organic phase was dried over MgSO4, filtered and concentrated under reduced pressure. The obtained residue was purified by flash chromatography with a gradient elution of cyclohexane / EtOAc from 100 / 00 to 80 / 20 to obtain 165mg

[0488] (42%) of 6-(2,4-dichlorophenyl)-2-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one.

[0489] LC / MS(m / z,MH+):321

[0490] Step 3: 6-(2,4-dichlorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl pivalate

[0491]

[0492] A mixture of 6-(2,4-dichlorophenyl)-2-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one (163 mg, 0.51 mmol), KCO (77 mg, 0.56 mmol) and pivaloyl chloride (67 mg, 0.56 mmol) in acetone (5 ml) was heated at 40° C. for 1 hour. After cooling to room temperature, the reaction mixture was filtered. The filtrate was concentrated under reduced pressure and the obtained residue was purified by flash chromatography with a gradient of cyclohexane / EtOAc from 100 / 00 to 90 / 10 to give 205 mg (96%) of 6-(2,4-dichlorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl pivalate.

[0493] LC / MS(m / z,MH+):405

[0494] Step 4: 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-yl pivalate

[0495]

[0496] Under Ar atmosphere, at -50 ° C, KHMDS (1M, 0.58 ml, 0.58 mmol) was added to a solution of 6-(2,4-dichlorophenyl)-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-yl pivalate (197 mg, 0.48 mmol) in THF (5 ml). The mixture was stirred for 30 min, and 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl) methanesulfonamide (173 mg, 0.49 mmol) was added to the resulting mixture. The reaction mixture was slowly warmed to 20 ° C and stirred for 90 minutes. The reaction mixture was quenched with saturated citric acid aqueous solution, then diluted with water and extracted twice with Et2O. The combined organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography with a gradient of cyclohexane / EtOAc from 100 / 00 to 90 / 10 to give 160 mg (61%) of 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulen-3-yl pivalate.

[0497] LC / MS(m / z,MH+):537

[0498] Intermediate 14: 4-(2,4-dichlorophenyl)-5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate

[0499]

[0500] Step 1: 5-Oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-yl trifluoromethanesulfonate

[0501]

[0502] 8-Hydroxy-3,4-dihydrobenzo[b]oxepin cooled at -20°C -5 (2H) -one (4.2g, 23.57mmol) (prepared according to WO 2018091153) and pyridine (2.82g, 2.89ml, 35.36mmol) in DCM (120ml) was added dropwise trifluoromethanesulfonic anhydride (8.14g, 6ml, 28.28mmol). The reaction mixture was stirred at 0 ° C for 30 minutes. Water (50ml) was added. The organic phase was separated and washed with a saturated aqueous solution of NaHCO (50ml). The organic phase was dried over MgSO, filtered, and concentrated under reduced pressure to obtain 7.40g (crude) of 5-oxo-2,3,4,5-tetrahydrobenzo [b] oxepin -8-yl trifluoromethanesulfonate.

[0503] LC / MS(m / z,MH+):311

[0504] Step 2: 5-Oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-Methyl formate

[0505]

[0506] To the compound 5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin To a solution of -8-yl trifluoromethanesulfonate (7.4 g, 23.85 mmol) in DMF (30 ml) and MeOH (15 ml) was added DIEA (3.15 g, 4.16 ml, 23.85 mmol) and Pd(dppf)Cl2 (1.10 g, 1.43 mmol) complexed with DCM, the suspension was degassed and purged with CO three times. The mixture was stirred at 75 ° C for 2 hours under CO (5 bar). The reaction was filtered through diatomaceous earth. The filtrate was diluted with water (400 ml) and extracted three times with EtOAc (300 ml). The combined organic phases were dried over Na2SO4, filtered, concentrated under reduced pressure, and the obtained residue was purified by flash chromatography with a gradient elution of heptane / ethyl acetate from 85 / 15 to 80 / 20 to obtain 4.6 g (88%) of 5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-Methyl formate.

[0507] LC / MS(m / z,MH+):221

[0508] Step 3: 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-Methyl formate

[0509]

[0510] Step 3 of Intermediate 14 was prepared by a procedure similar to that of Step 1 of Intermediate 13 from 5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin. -8-carboxylic acid methyl ester was prepared to give 1.13 g (67%) of 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin -8-Methyl formate.

[0511] LC / MS(m / z,MH+):365

[0512] Step 4: 4-(2,4-dichlorophenyl)-5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate

[0513]

[0514] Step 4 of Intermediate 14 was prepared by a procedure analogous to that of Step 4 of Intermediate 13 from 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin. -8-carboxylic acid methyl ester was prepared to give 0.48 g (31%) of 4-(2,4-dichlorophenyl)-5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate.

[0515] LC / MS(m / z,MH+):496

[0516] Intermediate 15: 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8-dihydronaphthalene-2-carboxylic acid methyl ester

[0517]

[0518] Step 1: 2-(2,4-Dichlorophenyl)-1-oxo-tetralin-6-carboxylic acid methyl ester

[0519]

[0520] Intermediate 15, Step 1 was prepared from methyl 1-oxotetralin-6-carboxylate following a procedure similar to that used to prepare Intermediate 13, Step 1 to give 459 mg (19%) of 4-(2,4-dichlorophenyl)-5-oxo-2,3,4,5-tetrahydrobenzo[b]oxepin. -8-Methyl formate.

[0521] LC / MS(m / z,MH+):349

[0522] Step 2: Methyl 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8-dihydronaphthalene-2-carboxylate

[0523]

[0524] Intermediate 15, step 2 was prepared following a procedure similar to that for the preparation of Intermediate 13, step 4 from 2-(2,4-dichlorophenyl)-1-oxo-tetralin-6-carboxylic acid methyl ester to give 0.48 g (31%) of 6-(2,4-dichlorophenyl)-5-(trifluoromethylsulfonyloxy)-7,8-dihydronaphthalene-2-carboxylic acid methyl ester.

[0525] LC / MS(m / z,MH+):481

[0526] Intermediate 16: (R)-3-(3-(8-bromo-6,7-dihydro-5H-benzo[7]annulene-9-yl)phenoxy)-1-(3-fluoropropyl)pyrrolidine

[0527]

[0528] Step 1: 6,7-Dihydro-5H-benzo[7]annulene-9-yl trifluoromethanesulfonate

[0529]

[0530] Trifluoromethanesulfonic anhydride (3.61 g, 2.15 ml, 12.8 mmol) was added dropwise to a mixture of 6,7,8,9-tetrahydro-5H-benzo[7]annulene-5-one (1.02 g, 6.37 mmol) and pyridine (0.765 g, 0.78 ml, 9.68 mmol) in DCM (30 ml) cooled at 0 ° C. The reaction mixture was stirred at 0 ° C for 30 minutes and at room temperature for 24 hours. Water (30 ml) was added. The organic phase was separated and washed with a saturated aqueous solution of NaHCO (50 ml). The organic phase was dried over MgSO, filtered, and concentrated under reduced pressure to obtain 1.18 g (63%) of 6,7-dihydro-5H-benzo[7]annulene-9-yl trifluoromethanesulfonate.

[0531] LC / MS(m / z,MH+):293

[0532] Step 2: (R)-3-(3-(6,7-dihydro-5H-benzo[7]annulene-9-yl)phenoxy)-1-(3-fluoropropyl)pyrrolidine

[0533]

[0534] Intermediate 16, Step 2 was prepared from (R)-1-(3-fluoropropyl)-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrrolidine (Intermediate 1) and 6,7-dihydro-5H-benzo[7]annulene-9-yl trifluoromethanesulfonate following a procedure analogous to that of Step 1 of Intermediate 2 to afford 0.34 g (46%) of (R)-3-(3-(6,7-dihydro-5H-benzo[7]annulene-9-yl)phenoxy)-1-(3-fluoropropyl)pyrrolidine.

[0535] LC / MS(m / z,MH+):366

[0536] Step 3: (R)-3-(3-(8-bromo-6,7-dihydro-5H-benzo[7]annulene-9-yl)phenoxy)-1-(3-fluoropropyl)pyrrolidine

[0537]

[0538] Step 3 of Intermediate 16 was prepared from (R)-3-(3-(6,7-dihydro-5H-benzo[7]annulen-9-yl)phenoxy)-1-(3-fluoropropyl)pyrrolidine following a procedure analogous to that used to prepare Step 3 of Intermediate 2 to afford 0.41 g (97%) of (R)-3-(3-(8-bromo-6,7-dihydro-5H-benzo[7]annulen-9-yl)phenoxy)-1-(3-fluoropropyl)pyrrolidine.

[0539] LC / MS(m / z,MH+):444

[0540] Intermediate 17: 8-(3-chlorophenyl)-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1 and isomer 2

[0541]

[0542] Step 1: 6-Bromo-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester

[0543]

[0544] To a mixture of 5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester (9.42 g, 43.2 mmol) in DCM (400 mL) was added pyridinium tribromide (16.12 g, 45.4 mmol) in portions. The reaction mixture was stirred at room temperature overnight. Water (500 ml) and ether (1 L) were added. The organic phase was separated and washed twice with water, dried over MgSO4, filtered and concentrated under reduced pressure to give 14.4 g (90%) of 6-bromo-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester.

[0545] LC / MS(m / z,MH+):297

[0546] Step 2: 5-Oxo-8,9-dihydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester

[0547]

[0548] To a solution of 6-bromo-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester (10 g, 33.66 mmol) in acetonitrile (100 mL) was added DABCO (7.4 mL, 67.32 mmol). The reaction mixture was heated to 55 ° C for 2.5 hours under Ar. Ether and 1N HCl were added. The organic phase was separated and washed twice with water, brine, dried over MgSO4, filtered and concentrated under reduced pressure. The resulting residue was then purified by flash chromatography eluting with a mixture of cyclohexane / EtOAc 85 / 15 to give 1.88 g (26%) of 5-oxo-8,9-dihydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester.

[0549] LC / MS(m / z,MH+):217

[0550] Step 3: 7-methyl-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester, racemic mixture

[0551]

[0552] At 0°C, under Ar, to a solution of 5-oxo-8,9-dihydro-5H-benzo[7]annulene-2-carboxylic acid methyl ester (1.88 g, 8.6 mmol) in THF (30 mL) was added 0.328 M cuprate solution (35 mL, 11.5 mmol), which was prepared by adding 15 mL of 1.6 N solution of methyl lithium in ether to a suspension of 2.5 g of CuI (13 mmol) in 25 mL of ether at 0°C under Ar. The reaction mixture was stirred at 0°C for 30 minutes. Ether (200 mL) and 1N HCl (200 mL) were added. The organic phase was separated and the aqueous phase was extracted with ether. The combined organic phase was washed with water, dried over MgSO4, filtered and concentrated under reduced pressure. The residue obtained is then purified by flash chromatography eluting with a mixture of cyclohexane / EtOAc 95 / 5 to give 1.95 g (86%) of methyl 7-methyl-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylate as a racemic mixture.

[0553] LC / MS(m / z,MH+):233

[0554] Step 4: 7-methyl-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, racemic mixture

[0555]

[0556] Step 4 of Intermediate 17 was prepared from methyl 7-methyl-5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-2-carboxylate following a procedure analogous to that of Step 1 of Intermediate 16 to afford 2.5 g (86%) of methyl 7-methyl-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate as a racemic mixture.

[0557] LC / MS(m / z,MH+):365

[0558] Step 5: 9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, an equimolar mixture of stereoisomers

[0559]

[0560] Step 5 of Intermediate 17 was prepared from (R)-1-(3-fluoropropyl)-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrrolidine (Intermediate 1) and methyl 7-methyl-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate following a procedure analogous to that used to prepare Step 1 of Intermediate 2 to afford 0.306 g (48%) of methyl 9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate as an equimolar mixture of stereoisomers.

[0561] LC / MS(m / z,MH+):438

[0562] Step 6: 8-Bromo-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, an equimolar mixture of stereoisomers

[0563]

[0564] Step 6 of Intermediate 17 was prepared following a procedure analogous to that used to prepare Step 3 of Intermediate 2 from methyl 9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate as an equimolar mixture of stereoisomers to afford 0.48 g (31%) of (R)-3-(3-(6,7-dihydro-5H-benzo[7]annulene-9-yl)phenoxy)-1-(3-fluoropropyl)pyrrolidine to afford 0.294 g (81%) of methyl 8-bromo-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate as an equimolar mixture of stereoisomers.

[0565] LC / MS(m / z,MH+):516

[0566] Step 7: 8-(3-chlorophenyl)-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1 and isomer 2

[0567]

[0568] An equimolar mixture of 8-bromo-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester stereoisomers (294 mg, 0.57 mmol), 3-chlorophenylboronic acid (98 mg, 0.63 mmol), Cs2CO3 (464 mg, 1.42 mmol), Pd(dppf)Cl2 complexed with DCM (28 mg, 34 μmol) in dioxane (7.6 ml) and water (3.2 ml) was heated at 80° C. for 1 hour. After cooling to room temperature, DCM (10 ml) and water (2 ml) were added, and the mixture was separated with a hydrophobic column. The organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure, and the residue obtained was purified by flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 95 / 05 to give 238 mg (76%) of 8-(3-chlorophenyl)-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester as an equimolar mixture of stereoisomers.

[0569] A mixture of methyl 8-(3-chlorophenyl)-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate was purified by chiral chromatography (column: I-Amylose-3 (250x30mm, 5μm); heptane 90% / EtOH [0.1% TEA] 10%) to give 88 mg of 8-(3-chlorophenyl)-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester isomer 1 and 88 mg of 8-(3-chlorophenyl)-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester isomer 2.

[0570] LC / MS(m / z,MH+):548

[0571] Intermediate 18: (R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thia -8-aminopivalate

[0572]

[0573] Step 1: (R)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thia -8-aminopivalate

[0574]

[0575] Intermediate 18 Step 1 Following a procedure similar to that for Intermediate 2 Method 2, 5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydrobenzo[b]thiazole was prepared from -8-yl pivalate (prepared according to WO 2018091153) and (R)-1-(3-fluoropropyl)-3-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]pyrrolidine (Intermediate 1) to give 160 mg (77%) of (R)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thiazolidine -8-yl pivalate.

[0576] LC / MS(m / z,MH+):484

[0577] Step 2: (R)-4-bromo-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thia -8-aminopivalate

[0578]

[0579] Intermediate 18, Step 2: Following a procedure analogous to that used to prepare Intermediate 2, Step 3: (R)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thiamine -8-yl pivalate was prepared to give 114 mg (62%) of (R)-4-bromo-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thiazolidine -8-yl pivalate.

[0580] LC / MS(m / z,MH+):562

[0581] Method A

[0582] Example 1:

[0583] (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid

[0584]

[0585] Step 1: (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0586]

[0587] A mixture of (R)-8-bromo-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (Intermediate 2) (100 mg, 0.20 mmol), 2,4-dichlorophenylboronic acid (43 mg, 0.22 mmol), Cs2CO3 (207 mg, 0.62 mmol), Pd(dppf)Cl2 (11 mg, 12.7 μmol) complexed with DCM in dioxane (1 ml) and water (0.4 ml) was heated to 80° C. for 30 minutes under microwave irradiation. After cooling to room temperature, DCM (10 ml) and water (2 ml) were added, and the mixture was separated with a hydrophobic column. The organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure, and the residue obtained was purified by flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 95 / 05 to give 72 mg (63%) of (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0588] LC / MS(m / z,MH+):568

[0589] Step 2: (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid

[0590]

[0591] To a mixture of (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (72 mg, 0.13 mmol) in MeOH (3 ml) was added NaOH 2M (185 μl, 0.37 mmol) and the reaction mixture was stirred at reflux for 3 hours. After cooling to room temperature, water (3 ml), DCM (3 ml) and HCl 1N were added to obtain a pH of 6-7. After separation with a hydrophobic column, the organic phase was concentrated under reduced pressure and the residue was purified by flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 90 / 10 to give 47 mg (66%) of (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid.

[0592] Method B

[0593] Example 10: (R)-8-(4,4-difluorocyclohexyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride

[0594]

[0595] Step 1: (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0596]

[0597] Step 1 of Example 10 was prepared according to a procedure similar to that of Step 1 of Preparative Example 1 from (R)-8-bromo-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (Intermediate 2) and (4,4-difluorocyclohex-1-en-1-yl)boronic acid to give 130 mg (61%) of (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0598] LC / MS (m / z, MH+):540.

[0599] Step 2: (R)-8-(4,4-difluorocyclohexyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0600]

[0601] A mixture of (R)-8-(4,4-difluorocyclohex-1-en-1-yl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (127 mg, 235 μmol), Pd / C 10% (12 mg, 117 μmol) in EtOH (9 ml) and EtOAc (5 ml) was hydrogenated at 65° C. and 7 bar of H2 for 24 h. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give 135 mg (crude) of (R)-8-(4,4-difluorocyclohexyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, which was used as is in the next step.

[0602] LC / MS(m / z,MH+):542

[0603] Step 3: (R)-8-(4,4-difluorocyclohexyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride isomer 1

[0604]

[0605] Step 3 of Example 10 was prepared from (R)-8-(4,4-difluorocyclohexyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester according to a procedure similar to that of Step 2 of Preparation Example 1 to give 100 mg (73.9%) of (R)-8-(4,4-difluorocyclohexyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride Isomer 1.

[0606] Method C

[0607] Example 28: 8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, Isomer 1

[0608]

[0609] Step 1: 8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, isomer 1

[0610]

[0611] Step 1 of Example 28 was prepared from 3-(3-bromobenzyl)-1-(3-fluoropropyl)pyrrolidine isomer 1 (Intermediate 11) and 8-(2,4-dichlorophenyl)-9-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester (Intermediate 9) according to a procedure similar to that of Step 1 of Preparative Example 1 to give 100 mg (82%) of 8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester, Isomer 1.

[0612] LC / MS(m / z,MH+):566

[0613] Step 2: Methyl 8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1

[0614]

[0615] Step 2 of Example 28 was prepared from 8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester isomer 1 according to a procedure similar to that of Step 2 of Example 1 to give 55 mg (56%) of 8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1.

[0616] Method D

[0617] Example 32: 8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid

[0618]

[0619] Step 1: tert-Butyl 3-((3-(8-(2,4-dichlorophenyl)-3-(methoxycarbonyl)-6,7-dihydro-5H-benzo[7]annulen-9-yl)phenyl)amino)azetidine-1-carboxylate

[0620]

[0621] A mixture of methyl 8-(2,4-dichlorophenyl)-9-(3-(((trifluoromethyl)sulfonyl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (Intermediate 12) (0.42 g, 0.73 mol), tert-butyl 3-aminoazetidine-1-carboxylate (0.26 g, 1.48 mmol), Cs2CO3 (0.74 g, 2,22 mmol), Pd(OAc)2 (18 mg, 0.075 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (62 mg, 0.10 μmol) in dioxane (5 ml) was heated to 130° C. for 1 hour under microwave irradiation. After cooling to room temperature, DCM (5 ml) and water (1 ml) were added. After separation on a hydrophobic column, the organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure, and the residue obtained was purified by flash chromatography eluting with a gradient of DCM / MeOH from 100 / 00 to 98 / 02 to give 0.26 g (60%) of tert-butyl 3-((3-(8-(2,4-dichlorophenyl)-3-(methoxycarbonyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)phenyl)amino)azetidine-1-carboxylate.

[0622] LC / MS(m / z,MH+):593

[0623] Step 2: 9-(3-(azetidin-3-ylamino)phenyl)-8-(2,4-dichlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0624] To a solution of tert-butyl 3-((3-(8-(2,4-dichlorophenyl)-3-(methoxycarbonyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)phenyl)amino)azetidine-1-carboxylate (0.26 g, 0.438 mmol) in DCM (3 ml) was added TFA (0.35 ml, 4.52 mmol). The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure. The obtained residue was purified on an SCX-2 column to give 0.17 g (81%) of methyl 9-(3-(azetidine-3-ylamino)phenyl)-8-(2,4-dichlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0625] LC / MS (m / z, MH+):493.

[0626] Step 3: 8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0627]

[0628] Step 3 of Example 32 was prepared from methyl 9-(3-(azetidin-3-ylamino)phenyl)-8-(2,4-dichlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate following a procedure analogous to that of Step 3 of Intermediate 1 to afford 63 mg (33%) of methyl 8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0629] LC / MS(m / z,MH+):554

[0630] Step 4: 8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid

[0631]

[0632] Step 4 of Example 32 was prepared from 8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester according to a procedure similar to that of Preparative Example 1, to give 45.6 mg (74%) of 8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid.

[0633] Example 33: (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride

[0634]

[0635] Step 1: (R)-tert-butyl 3-((3-(8-(2,4-dichlorophenyl)-3-(methoxycarbonyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)phenyl)amino)pyrrolidine-1-carboxylate

[0636]

[0637] Step 1 of Example 33 was prepared according to a procedure analogous to that of Step 1 of Example 32 from methyl 8-(2,4-dichlorophenyl)-9-(3-(((trifluoromethyl)sulfonyl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate (Intermediate 12) and (R)-1-BOC-3-aminopyrrolidine to give 160 mg (13%) of tert-butyl (R)-3-((3-(8-(2,4-dichlorophenyl)-3-(methoxycarbonyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)phenyl)amino)pyrrolidine-1-carboxylate.

[0638] LC / MS(m / z,MH+):607

[0639] Step 2: (R)-8-(2,4-dichlorophenyl)-9-(3-(pyrrolidin-3-ylamino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0640]

[0641] Step 2 of Example 33 was prepared from (R)-tert-butyl 3-((3-(8-(2,4-dichlorophenyl)-3-(methoxycarbonyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)phenyl)amino)pyrrolidine-1-carboxylate according to a procedure similar to that of Step 2 of Example 32 to give 120 mg (90%) of methyl (R)-8-(2,4-dichlorophenyl)-9-(3-(pyrrolidin-3-ylamino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylate.

[0642] LC / MS (m / z, MH+):507.

[0643] Step 3: (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester

[0644]

[0645] Step 3 of Example 33 was prepared from (R)-8-(2,4-dichlorophenyl)-9-(3-(pyrrolidin-3-ylamino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester following a procedure analogous to that of Step 3 of Intermediate 1 to afford 114 mg (44%) of (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester.

[0646] LC / MS(m / z,MH+):567

[0647] Step 4: (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride

[0648]

[0649] Step 4 of Example 33 was prepared from (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester according to a procedure similar to that of Preparative Example 1, to give 98 mg (83%) of (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride.

[0650] Method E

[0651] Example 35: (R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]oxepin -8-Formic acid hydrochloride

[0652]

[0653] Step 1: (R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate

[0654]

[0655] Example 35, Step 1: According to a procedure similar to that of Preparative Example 1, Step 1 was prepared from (R)-1-(3-fluoropropyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine (Intermediate 1) and 4-(2,4-dichlorophenyl)-5-(((trifluoromethyl)sulfonyl)oxy)-2,3-dihydrobenzo[b]oxepin. -8-methyl carboxylate (Intermediate 14) to give 57 mg (33%) of (R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]oxepin -8-Methyl formate.

[0656] LC / MS(m / z,MH+):570

[0657] Step 2: (R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]oxepin -8-Formic acid hydrochloride

[0658]

[0659] Step 2 of Example 28 was prepared by a procedure similar to that of Step 2 of Preparative Example 1 from (R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]oxepin. -8-carboxylic acid methyl ester was prepared to give 49 mg (83%) of (R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]oxepin -8-formic acid hydrochloride.

[0660] Method F

[0661] Example 34: (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol

[0662]

[0663] Step 1: (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-yl pivalate

[0664]

[0665] Step 1 of Example 34 was prepared from (R)-1-(3-fluoropropyl)-3-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)pyrrolidine (Intermediate 1) and 8-(2,4-dichlorophenyl)-9-(((trifluoromethyl)sulfonyl)oxy)-6,7-dihydro-5H-benzo[7]annulen-3-yl pivalate (Intermediate 13) according to a procedure similar to that of Step 1 of Preparative Example 1 to give 105 mg (42%) of (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-yl pivalate.

[0666] LC / MS(m / z,MH+):610

[0667] Step 2: (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol

[0668]

[0669] Step 2 of Example 34 was prepared from (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-yl pivalate according to a procedure similar to that of Step 2 of Preparative Example 1 to give 55 mg (56%) of (R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulen-3-ol.

[0670] Example 41: (R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thiazole -8-ol

[0671]

[0672] Step 1: (R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thiazole -8-aminopivalate

[0673]

[0674] Example 41, Step 1: According to a procedure similar to that of Preparation Example 1, Step 1: (R)-4-bromo-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thiamine was used. -8-yl pivalate (Intermediate 18) and 2,4-dichlorophenylboronic acid to give 67 mg (69%) of (R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thiazolidine -8-yl pivalate.

[0675] LC / MS(m / z,MH+):628

[0676] Step 2: (R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thiazole -8-ol

[0677]

[0678] Example 41, step 2: According to the procedure similar to that of Preparation Example 1, step 2 was prepared from (R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thiazol-2-yl ... -8-yl pivalate was prepared to give 23 mg (40%) of (R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thiazolidine -8-ol.

[0679] Method G

[0680] Example 36: 8-(3-chlorophenyl)-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, Isomer 1

[0681]

[0682] Example 36 was prepared from 8-(3-chlorophenyl)-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid methyl ester isomer 1 according to a procedure similar to that of step 2 of preparation example 1 to give 51 mg (59%) of 8-(3-chlorophenyl)-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1.

[0683] Examples:

[0684] The compounds according to Table 1a above were subjected to pharmacological testing for determining their degradation effect on the estrogen receptor.

[0685] Test: Estrogen receptor degradation activity

[0686] The test involves measuring the in vitro degradation activity of the compounds of Table 1a.

[0687] Degradation activity of ERα was measured using breast cancer cells in a cellular Western blot assay as described below.

[0688] MCF7 cells (ATCC) were seeded in red phenol-free MEMα medium (Invitrogen) containing 5% charcoal dextran-treated FBS at a concentration of 10,000 cells / 30 μL / well in 384-well microplates (collagen coated). The next day, 9 points of each compound were added to the cells in a final concentration ranging from 0.3-0.0000018 μM (Table 2) or 0.1 μM of Fulvestrant (used as a positive control) in 2.5 μL cells: 1:5 dilutions were added to the cells. 4 hours after compound addition, cells were fixed by adding 25 μL of formalin (5% formalin with a final concentration of 0.1% triton) for 10 minutes at room temperature, and then washed twice with PBS. Then, 50 μL of LI-COR blocking buffer containing 0.1% Triton was added to the plate for 30 minutes at room temperature. LI-COR blocking buffer was removed and cells were incubated overnight in a cold room with 50 μL of anti-ER rabbit monoclonal antibody (Thermo scientific MA1-39540) diluted 1:1000 in LI-COR blocking buffer containing 0.1% tween-20. Wells treated with blocking buffer but without antibody were used as background controls. The wells were washed twice with PBS (0.1% tween-20) and incubated at 37°C for 60 minutes in LI-COR (0.1% tween-20) containing goat anti-rabbit antibody Alexa 488 (1:1000) and Syto-64a DNA dye (2 μM final concentration). The cells were then washed 3 times in PBS and scanned in an ACUMEN detector (TTP-Labtech). The integrated intensity of green and red fluorescence was measured to determine the levels of ERα and DNA, respectively.

[0689] In this test, the degradation activity of estrogen receptor is determined by the concentration that degrades 50% of the estrogen receptor (or IC 50 ) is given in nM.

[0690] The % reduction in ERa levels was determined as follows: % inhibition = 100*(1 - (sample-fulvestrant:DMSO-fulvestrant)).

[0691] The following Table 2 shows the estrogen receptor degradation activity results of the compounds of Table 1a tested at 0.3 μM, and demonstrates that the compounds of the present invention have significant degradation activity on the estrogen receptor.

[0692] Table 2 :

[0693]

[0694]

[0695]

[0696] Therefore, it is obvious that the test compound according to the present invention has degradation activity on estrogen receptor, IC50 is less than 1 μM and the degradation level is greater than 50%. Therefore, the compound of formula (I) can be used for the preparation of drugs, especially drugs as degraders of estrogen receptor.

[0697] Furthermore, it is apparent that comparative compounds 1a and 2a, which have an -O-pyrrolidine side chain at the meta position and both are (S) stereoisomers, are inactive.

[0698] Compound 1a can be compared with compound N°51 of WO 2017 / 140669 A1 and compound N°43d of Youssef El-Ahmad et al. (J. Med. Chem., 2020, 63, 512-528). Compound 2a can be compared with compound N°217 of WO 2017 / 140669 A1. These three compounds of the prior art have an O-pyrrolidine side chain in the para position, are (S) stereoisomers, and have degradation activity on estrogen receptors.

[0699] Thus, the data suggest that changes in the side chain lead to a loss of biological activity when only the side chain is moved from the para position to the meta position.

[0700] Surprisingly, activity was retained only after the stereochemistry was changed from (S) to (R).

[0701] Therefore, also provided herein is a medicament comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

[0702] Also provided herein is a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use as a medicament.

[0703] Also provided herein are compounds of formula (I) as defined above, or pharmaceutically acceptable salts thereof, for use in therapy, particularly as inhibitors and degraders of estrogen receptors.

[0704] Also provided herein is a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use in the treatment of ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation.

[0705] A particular aspect is a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.

[0706] In embodiments, the cancer is a hormone-dependent cancer.

[0707] In another embodiment, the cancer is an estrogen receptor dependent cancer, in particular the cancer is an estrogen receptor alpha dependent cancer.

[0708] In another embodiment, the cancer is selected from breast cancer, ovarian cancer, endometrial cancer, prostate cancer, uterine cancer, cervical cancer, and lung cancer, or metastases thereof.

[0709] In another embodiment, the metastasis is a brain metastasis.

[0710] In another embodiment, the cancer is breast cancer. In particular, the breast cancer is estrogen receptor positive breast cancer (ERα positive breast cancer).

[0711] In another embodiment, the cancer is resistant to anti-hormone therapy.

[0712] In further embodiments, the compounds of Formula (I) are used as single agents or in combination with other agents such as CDK4 / 6, mTOR or PI3K inhibitors.

[0713] According to another aspect, provided herein is a method of treating the above indicated pathological conditions, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In an embodiment of this method of treatment, the subject is a human.

[0714] Also provided herein is the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament useful for the treatment of any of the above indicated pathological conditions, more particularly useful for the treatment of cancer.

[0715] Also provided herein are pharmaceutical compositions comprising a compound of formula (I) as an active ingredient. These pharmaceutical compositions comprise an effective dose of at least one compound of formula (I) or a pharmaceutically acceptable salt thereof, and also at least one pharmaceutically acceptable excipient.

[0716] The excipients are selected from the customary excipients known to those skilled in the art, depending on the desired pharmaceutical form and method of administration.

[0717] In pharmaceutical compositions for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active ingredient of the above formula (I) or its base, acid, zwitterion or salt thereof can be administered to animals and humans in a unit administration form, as a mixture with conventional pharmaceutical excipients for the treatment of the above disorders or diseases.

[0718] Suitable unit administration forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular and intranasal administration forms, forms for inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration, rectal administration forms and implants. For topical application, the compounds of formula (I) can be used in creams, gels, ointments or lotions.

[0719] As an example, a unit administration form of a compound of formula (I) in the form of a tablet may comprise the following components:

[0720]

[0721] There may be specific cases where higher or lower doses are appropriate. According to routine practice, the appropriate dose for each patient is determined by the physician according to the mode of administration and the weight and response of the patient.

Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof: in: - R1 and R2 independently represent a hydrogen atom or a deuterium atom; -R3 represents a hydrogen atom, a -COOH group or a -OH group; - R3′ and R3″ independently represent a hydrogen atom, a methyl group, a methoxy group, a chlorine atom, a fluorine atom, or a cyano group; -R4 represents a hydrogen atom or a fluorine atom; - R5 and R5' independently represent a hydrogen atom or a fluorine atom; -R6 represents a group selected from the following: ■ phenyl, which is optionally substituted by 1 to 3 substituents independently selected from the group consisting of a halogen atom; a (C1-C6)alkyl group optionally substituted by a cyano group or an -OH group; a (C1-C6)fluoroalkyl group; a (C3-C6)cycloalkyl group; a (C1-C6)alkoxy group; a (C1-C6)fluoroalkoxy group; a cyano group; a trifluoromethylsulfonyl group; a (C1-C4)alkylthio group; a (C1-C4)fluoroalkylthio group; a (C1-C4)alkylsulfonyl group; and an -OH group; ■ a fused phenyl group selected from a phenyl group fused to a (C3-C6)cycloalkyl group, the (C3-C6)cycloalkyl ring of which optionally contains unsaturation, and wherein the fused phenyl group is optionally substituted with 1 to 3 substituents independently selected from a (C1-C3)alkyl group, a hydroxyl group, a halogen atom, a (C1-C6)fluoroalkyl group and a (C1-C3)alkoxy group; ■ a bicyclic group containing 5 to 12 carbon atoms, optionally containing 1 to 2 degrees of unsaturation; optionally substituted by 1 to 4 substituents independently selected from the group consisting of fluorine atoms, -OH groups, (C1-C3)alkyl groups, (C1-C3)fluoroalkyl groups, (C1-C3)alkoxy groups, (C1-C3)fluoroalkoxy groups and oxo groups; ■ a heteroaryl group containing 2 to 9 carbon atoms and containing from 1 to 3 heteroatoms independently selected from oxygen, nitrogen and sulfur and at least 5 atoms including carbon atoms and heteroatoms, such as a pyridyl group, a pyridone group or a pyrrolyl group, the heteroaryl group being optionally substituted by 1 to 3 substituents independently selected from a halogen atom, a (C1-C6)alkyl group, a (C1-C6)fluoroalkyl group, a (C1-C6)alkoxy group, a (C1-C6)fluoroalkoxy group, a cyano group, a carbamoyl group and a -OH group; ■ a cycloalkyl group containing 3 to 7 carbon atoms, which is saturated or partially saturated and optionally substituted with 1 to 4 substituents independently selected from: o fluorine atom, -OH group, (C1-C3) alkyl group, (C1-C3) fluoroalkyl group, (C1-C3) alkoxy group, (C1-C3) fluoroalkoxy group, oxo group, o (C3-C6) cycloalkyl and phenyl, wherein the (C3-C6) cycloalkyl or phenyl is optionally substituted with one or two halogen atoms or (C1-C3) alkyl; ■ (C3-C6)cycloalkyl (C1-C3)alkyl, which is optionally substituted on the cycloalkyl by 1 to 4 substituents independently selected from the group consisting of a fluorine atom, an -OH group, a (C1-C4)alkyl group, a (C1-C3)fluoroalkyl group, a (C1-C3)fluoroalkoxy group and an oxo group; ■ 4- to 7-membered heterocycloalkyl containing 1 or 2 heteroatoms independently selected from oxygen, nitrogen and sulfur, such as tetrahydropyranyl or tetrahydrofuranyl, said heterocycloalkyl being saturated or partially saturated and optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluorine atoms, (C1-C3)alkyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, oxo, (C1-C3)alkoxy and -OH groups; ■ (C1-C6) alkyl, such as isobutyl or ethylbutyl, optionally substituted with 1 to 4 substituents independently selected from the group consisting of fluorine atoms, (C1-C3) alkoxy, (C1-C3) fluoroalkoxy and -OH groups; and ■phenyl(C1-C2)alkyl, the phenyl being optionally substituted by 1 to 3 substituents independently selected from the group consisting of: halogen atoms; (C1-C3)alkyl; (C1-C3)fluoroalkyl; (C1-C3)alkoxy; (C1-C3)fluoroalkoxy; cyano; and -OH groups; -X represents -CH2-, -O- or -S-; -Y represents -CH2-, -O- or -NH-; - R7 independently represents a (C1-C3)alkyl group such as a methyl group, a halogen atom such as a fluorine atom, a cyano group, or a (C1-C3)fluoroalkyl group such as a trifluoromethyl group; -R8 represents a hydrogen atom, or a (C1-C3) alkyl group or a cyclopropyl group; -n is 0, 1, or 2; -m is 0 or 1; and -p is 0 or 1; Provided that when Y represents -O- or -NH-, and p is 1, then the asymmetric carbon of the pyrrolidine attached to Y has the (R) configuration.

2. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1, characterized in that: R1 and R2 are hydrogen atoms.

3. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that: R3 is a -COOH group.

4. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, characterized in that: R3' and R3" represent a hydrogen atom.

5. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, characterized in that: R4 represents a hydrogen atom.

6. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, characterized in that: X represents -O- or -CH2-, and preferably X represents -CH2-.

7. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 6, characterized in that: R5 and R5' represent a hydrogen atom.

8. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, characterized in that: R6 represents a phenyl group which is optionally substituted by 1 or 2 substituents independently selected from a chlorine atom, a fluorine atom and a methyl group.

9. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, characterized in that: R6 represents a cyclohexyl group which is substituted by 1 or 2 substituents independently selected from a chlorine atom and a methyl group.

10. The compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 7, characterized in that: R6 represents a cyclopentyl group.

11. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, characterized in that: R7 represents a methyl group or a fluorine atom and n is 0 or 1.

12. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 11, characterized in that: R8 represents a hydrogen atom or a methyl group.

13. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, wherein: Y represents -O-.

14. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 13, wherein: m is 1.

15. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 14, wherein: p is 1.

16. A compound of formula (I) or a pharmaceutically acceptable salt thereof, in particular a hydrochloride thereof, according to any one of claims 1 to 15, characterized in that The compound is selected from the following compounds: -(R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (1) -(R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-8-phenyl-6,7-dihydro -5H-Benzo[7]annulene-3-carboxylic acid, (2) -(R)-8-(2-chlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (3) -(R)-8-(2-chloro-4-methylphenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (4) -(R)-8-(2-chloro-4-fluorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (5) -(R)-8-(4-chloro-2-fluorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (6) -(R)-8-(2-fluoro-4-methylphenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (7) -(R)-8-(2,4-dimethylphenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (8) -(R)-8-(2-chloro-3-fluorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (9) -(R)-8-(4,4-difluorocyclohexyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, (10) -(R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-8-(4-methylcyclohexyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1, (11) -(R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-8-(4-methylcyclohexyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 2, (12) -(R)-8-(4,4-dimethylcyclohexyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride, (13) -(R)-8-cyclopentyl-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (14) -(R)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-8-phenyl -6,7-Dihydro-5H-benzo[7]annulene-3-carboxylic acid, (15) -(R)-8-(2-chlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (16) -(R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (17) -(R)-8-(4-fluoro-2-methylphenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (18) -(R)-9-(2-Fluoro-3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-8-phenyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride, (19) -(R)-8-(2-chlorophenyl)-9-(2-fluoro-3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride, (20) -(R)-8-(2,4-dichlorophenyl)-9-(2-fluoro-3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride, (21) -(R)-9-(5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-8-phenyl -6,7-Dihydro-5H-benzo[7]annulene-3-carboxylic acid, (22) -(R)-8-(2-chlorophenyl)-9-(5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (23) -(R)-8-(2-chlorophenyl)-9-(5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)-2-methylphenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (24) -(R)-9-(2-Fluoro-5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-8-phenyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride, (25) -(R)-8-(2-chlorophenyl)-9-(2-fluoro-5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, hydrochloride, (26) -(R)-8-(2,4-dichlorophenyl)-9-(2-fluoro-5-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, (27) -8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1, (28) -8-(2-chlorophenyl)-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, (29) -8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, (30) -8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)methyl)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (31) -8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, (32) -(R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)amino)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid hydrochloride, (33) -(R)-8-(2,4-dichlorophenyl)-9-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-ol, (34) -(R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]oxepin -8-carboxylic acid hydrochloride, (35) -8-(3-chlorophenyl)-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 1, (36) -8-(3-chlorophenyl)-9-(3-(((R)-1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7-methyl-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid, isomer 2, (37) -(R)-3-(3-(8-(2,4-dichlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)phenoxy)-1-(3-fluoropropyl)pyrrolidine, (38) -(R)-3-(3-(8-(2-chlorophenyl)-6,7-dihydro-5H-benzo[7]annulene-9-yl)phenoxy)-1-(3-fluoropropyl)pyrrolidine, (39) -(R)-6-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-7,8-dihydronaphthalene-2-carboxylic acid hydrochloride, (40), and -(R)-4-(2,4-dichlorophenyl)-5-(3-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-2,3-dihydrobenzo[b]thia -8-ol, (41).

17. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 16, wherein: The compound of formula 1G: -- wherein R1, R2, R3', R3", R4, R5, R5', R6, R7, R8, m, n, p, X and Y are as defined in any one of claims 1 to 15, and R3a is a hydrogen atom or a carboxylate such as -COOMe, -COOEt, or a protected -OH such as, for example, O-pivaloyl- is converted to a compound of formula (I) in the presence of a hydroxide ion source such as NaOH or LiOH in solution in methanol, said step optionally being preceded by a step for obtaining compound 1G, wherein a compound of formula 1F: -- wherein R1, R2, R3', R3", R4, R5, R5', R7, R8, m, n, p, X and Y are as defined in any one of claims 1 to 15, and R3a is as defined above-- Subjected to Suzuki coupling with a boronic acid reagent R6B(OR')2 wherein -B(OR')2 is a boronic acid or pinacol ester and R6 is as defined in any one of claims 1 or 8 to 10.

18. A method for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 16, wherein: The compound of formula 1Fa: -- wherein R1, R2, R3, R3', R3", R4, R5, R5', R7, R8, m, n, p, X and Y are as defined in any one of claims 1 to 15 -- undergoes reaction with a boronic acid reagent R6B(OR')2 -- wherein - B(OR')2 is boronic acid or pinacol ester and R6 is as defined in any one of claims 1 or 8 to 10 --Suzuki coupling, said step optionally being preceded by a step for obtaining compound 1Fa, wherein a compound of formula 1F: -- wherein R1, R2, R3', R3", R4, R5, R5', R7, R8, m, n, p, X and Y are as defined in any one of claims 1 to 15, and R3a is a hydrogen atom or a carboxylate such as -COOMe, -COOEt, or protected -OH such as O-pivaloyl- The conversion to compound 1Fa is carried out in solution in methanol in the presence of a hydroxide ion source such as NaOH or LiOH.

19. An intermediate compound selected from the group consisting of compounds of formula 1E, 1F, 1G and 1Fa or any pharmaceutically acceptable salt thereof: wherein R1, R2, R3, R3', R3", R4, R5, R5', R6, R7, R8, m, n, p, X and Y are as defined in any one of claims 1 to 15, and R3a is a hydrogen atom or a carboxylate such as -COOMe, -COOEt, or a protected -OH such as O-pivaloyl.

20. An intermediate compound of formula 1D' or any pharmaceutically acceptable salt thereof: wherein R1, R2, R4, R5, R5′, R7, Y, p and n are as defined in any one of claims 1 to 15.

21. A drug, characterized in that The medicament comprises a compound of formula (I) according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof.

22. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises a compound of formula (I) according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.

23. A compound of formula (I) or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 16 for use as an inhibitor and degrader of estrogen receptors.

24. A compound of formula (I) according to any one of claims 1 to 16 or a pharmaceutically acceptable salt thereof for use in the treatment of ovulatory dysfunction, cancer, endometriosis, osteoporosis, benign prostatic hypertrophy or inflammation.

25. A compound of formula (I) or a pharmaceutically acceptable salt thereof for use according to claim 24, for use in the treatment of cancer.

Citation Information

Patent Citations

  • 6,7-dihydro-5h-benzo[7]annulene derivatives as estrogen receptor modulators

    WO2017140669A1

  • Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof

    WO2018091153A1

  • Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-YL]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate

    WO2020049153A1